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Dual-energy X-ray absorptiometry 
(DXA) is commonly used to measure 
bone mineral density (BMD) and 
diagnose osteoporosis. However, 
BMD accounts for only 60% of bone 
strength, i.e., changes in bone quality 
as well as density may increase the 
fracture risk. This study aimed to 
characterize bone quality in different 
cohorts of patients using bone 
histomorphometry, microcomputed 
tomography (micro-CT), and Fourier 
transform infrared spectroscopic 
imaging (FTIRI).
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ABSTRACT 
 
Osteoporosis is the most common metabolic bone disease characterized by low bone mass 
and altered material properties. Compromised bone strength predisposes the individual to 
fractures. Dual-energy X-ray absorptiometry (DXA) is commonly used to measure bone 
mineral density (BMD). However, BMD accounts for only 60% of bone strength, i.e., 
changes in bone quality as well as density may increase the fracture risk. This study aimed 
to characterize bone quality in different cohorts of patients using bone histomorphometry, 
microcomputed tomography (micro-CT), and Fourier transform infrared spectroscopic 
imaging (FTIRI). 
Iliac crest biopsies were collected from different cohorts: i) patients with osteoporosis 
(OP, n=15) or renal osteodystrophy (ROD, n=11) or healthy controls (n=10), ii) patients with 
atypical femoral fractures (AFFs, n=4), ii) children with suspected primary osteoporosis 
(n=24), and iv) children after solid organ transplantation (n=19). Bone histomorphometry 
was performed to examine bone remodeling and turnover, micro-CT to study bone 
microarchitecture, and FTIRI to study bone composition. The results were correlated with 
fracture history, clinical characteristics, densitometry, and biochemistry when appropriate. 
The reproducibility of bone histomorphometry and the agreement between bone 
histomorphometry and micro-CT were studied. Further, the incidence of AFFs was 
investigated within our hospital catchment area.   
 Repeated measurements for structural bone parameters revealed linear correlation 
coefficients (ρ) of 0.87-0.92 (CV 8.3-27.2%) for histomorphometry and of 0.66-0.94 (CV 4.4-
23.4%) for micro-CT. There were no significant differences in reproducibilities in the 
samples obtained from the different study groups (OP, ROD, healthy controls). When 
comparing the techniques, cancellous bone volume (BV/TV), trabecular thickness, and 
trabecular number displayed moderate correlations (ρ=0.39-0.62, p<0.05), and the agreement 
for BV/TV was highest in OP samples. The incidence of AFFs among patients receiving 
biphosphonates was 0.61 fractures/1000 patients per year within the catchment area of 
Kuopio University Hospital, compared to 0.0067/1000 per year among untreated subjects. 
Histomorphometry in 4 patients revealed a low cancellous bone volume. Bone formation 
and resorption parameters were found to be low. Based on FTIRI, a high phosphate-to-
amide I ratio and a high collagen maturity were detected in comparison with normal 
samples. Children with vertebral fracture (n=14) were examined, in 36% of cases low 
cancellous bone volume (BV/TV <-1.0 SD) was detected by histomorphometry, and in 64% 
of the children the bone turnover rate was abnormal. Children with vertebral fractures had 
lower a carbonate-to-phosphate ratio, higher collagen maturity, and a narrower collagen 
distribution (p<0.05) than children without vertebral fracture. In children after solid organ 
transplantation (n=19), 21% had sustained peripheral fractures and 58% had suffered 
vertebral compression fractures. Histomorphometric analyses showed low cancellous bone 
volume (<-1.0 SD) in six children (32%) and decreased trabecular thickness in 14 children 
(74%). Seven children (37%) had a high bone turnover and six children (32 %) had low 
turnover. 
 
 
 
VI 
There was moderate agreement between bone histomorphometry and micro-CT using 
clinical bone samples. The reproducibility was not affected by the health status of bone. The 
overall incidence of AFFs was low. The poor fracture resistance in some patients on long-
term bisphosphonate-therapy could be explained by low bone formation, and changes in 
bone composition. Further, changes in bone composition were found among fracture-prone 
children who had sustained vertebral fracture. The changes in these children might 
contribute to their greater propensity to sustain vertebral fractures. A great heterogeneity in 
the histological findings was found in children after organ transplantation, and the results 
were unpredictable if only non-invasive methods were available. The observed changes in 
bone quality rather than the actual loss of cancellous bone, might explain the increased 
fracture risk in pediatric solid organ transplant recipients. Based on the present results, 
histomorphometry is needed in clinical practice to study remodeling balance in bone, with 
the other potential methods available to study bone quality being complementary.  
 
National Library of Medical Classification: WE 200, WE 225, WE 250, WN 206 
Medical Subject Headings: Adult; Bone and Bones/ anatomy & histology; Bone and Bones/metabolism; Bone 
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Spectroscopy, Fourier Transform Infrared; Transplantation/adverse effects; X-Ray Microtomography 
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TIIVISTELMÄ  
 
Osteoporoosi eli luukato on yleisin metabolinen luustosairaus. Osteoporoosissa luun määrä 
ja laatuominaisuudet ovat alentuneet altistaen luumurtumille. Luuntiheysmittausta (DXA) 
käytetään luun mineraalitiheyden (BMD) mittaamiseen. BMD selittää kutenkin vain 60% 
luun lujuudesta ja näin ollen muut luun laatuominaisuudet voisivat selittää lisääntynyttä 
murtumaherkkyyttä. Tämän tutkimuksen tavoitteena oli määrittää luunäytteiden 
laatuominaisuuksia eri potilas-aineistoissa käyttäen tutkimusmenetelminä kvantitatiivista 
luun histomorfometriaa, mikrotietokonetomografiaa (mikro-TT) ja Fourier-muunnos-
infrapunaspektrometriaa (FTIRI).     
Luunäytteet kerättiin suoliluuharjusta eri aineistoista: i) osteoporoosia (OP, n=15) tai 
renaalista osteodystrofiaa sairastavilta potilailta (ROD, n=11) sekä terveiltä yksilöiltä (n=10), 
ii) epätyypillisiä reisiluumurtumia sairastaneilta potilailta (n=4), iii) lapsilta, joilla epäiltiin 
primaarista osteoporoosia (n=24) ja iv) elinsiirron saaneilta lapsilta (n=19). 
Histomorfometriaa käytettiin luun uudismuodostuksen ja vaihtuvuuden tarkasteluun, 
mikro-TT:aa luun mikroarkkitehtuurin tutkimiseen ja FTIRI:aa luun koostumuksen 
selvittämiseen. Tuloksia verrattiin potilaiden murtumahistoriaan, kliinisiin muuttujiin, 
luuntiheyteen ja veren laboratorioarvoihin. Histomorfometria-menetelmän toistettavuus 
määritettiin. Histomorfometriasta ja mikro-TT:sta saatujen tulosten välinen korrelaatio 
laskettiin. Lisäksi selvitettiin epätyypillisten reisiluun murtumien esiintyvyys 
sairaanhoitopiirimme alueella.  
Toistettavuusmittauksissa luun rakenteellisten parametrien korrelaatiokerroin (ρ) oli 
histomorfometrialla 0.87-0.92 (CV 8.3-27.2%) ja mikro-TT:lla 0.66-0.94 (CV 4.4-23.4%). 
Toistettavuudessa ei ollut eroa eri tutkimusryhmien (OP, ROD, normaalinäytteet) välillä. 
Tilastollisesti merkitsevä korrelaatio (ρ=0.39-0.62, p<0.05) tekniikoita verrattaessa voitiin 
osoittaa hohkaluutilavuudelle (BV/TV), palkkien paksuudelle (Tb.Th) ja palkkien määrälle 
(Tb.N). Korrelaatiot olivat parhaimmat OP näytteille. Epätyypillisten reisiluumurtumien 
esiintyvyys vuodessa Kuopion yliopistollisen sairaalan sairaanhoitopiirin alueella 
bisfosfonaatteja käyttäneillä naispotilailla oli 0.61 murtumaa/1000 potilasta. Vastaavasti 
vuosittainen esiintyvyys naisilla, jotka eivät olleet saaneet bisfosfonaatteja, oli 0.0067/1000 
potilasta. Neljälle potilaalle tehtiin luun histomorfometria ja heillä havaittiin matala 
hohkaluutilavuus. Luun muodostuminen ja hajotus olivat hidasta. FTIRI:lla havaittiin 
korkeampi fosfaatti/amidi I suhde ja korkeampi kollageenin kypsyysaste verrattuna 
normaalinäytteisiin. Nikamamurtumia sairastaneista lapsista (n=14) 36%:lla oli matala 
hohkaluutilavuus (BVTV <-1.0 SD) ja 64%:lla luun vaihtuvuusnopeus oli poikkeava. 
Nikamamurtumia sairastaneilla lapsilla oli matalampi karbonaatti/fosfaatti suhde, 
korkeampi kollageenin kypsyysaste ja kapeampi kollageenin jakautumisaste (p<0.05) kuin 
nikamamurtumia sairastamattomilla lapsilla. Elinsiirron saaneista lapsista (n=19) 21% oli 
sairastanut perifeerisiä murtumia ja 58% nikamamurtumia. Histomorfometria-tutkimuksen 
perusteella hohkaluun tilavuus oli matala (<-1 SD) kuudella lapsella (32%) ja palkkien 
paksuus oli alentunut 14 lapsella (74%). Luun vaihtuvuus oli nopeaa seitsemällä lapsella 
(37%) ja hidasta kuudella lapsella (32%).        
 
 
 
VIII 
Luun histomorfometrian ja mikro-TT:an välinen korrelaatio kliinisillä luunäytteillä oli 
kohtalainen. Menetelmien välinen toistettavuus ei ollut riippuvainen aineenvaihdunnan 
tilasta. Epätyypillisten reisiluumurtumien esiintyvyys oli alhainen. Lisääntynyt 
murtumaherkkyys näillä potilailla voi selittyä hitaalla luun muodostuksella ja muutoksilla 
luun koostumuksessa. Nikamamurtumia sairastaneilla lapsilla havaittiin poikkeavuuksia 
luun koostumuksessa, mikä voisi selittää lisääntynyttä herkkyyttä kokea kyseisiä 
murtumia. Elinsiirron saaneilla lapsilla luun histologiset löydökset olivat moninaiset ja 
tuloksia ei voitu ennustaa ei-kajoavilla menetelmillä. Osoitetut luun laadun muutokset, 
todennäköisimmin kuin luun määrän alentuminen, voisivat selittää lisääntynyttä 
murtumariskiä näillä lapsilla. Luun histomorfometriaa voidaan hyödyntää niin kliinisessä 
työssä kuin tutkimustyössä luun uudismuodostuksen tutkimiseen. Muut luun laadun 
tutkimiseen tarkoitetut menetelmät ovat täydentäviä.  
 
Yleinen Suomalainen asiasanasto: aikuiset; elimensiirto; lapset; luunmurtumat; luuston sairaudet; 
osteoporoosi; tietokonetomografia; 
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1 Introduction  
Osteoporosis is the most common metabolic bone disease worldwide and it has emerged as 
a health concern for all age groups (Cooper 1989). The number of patients suffering from 
osteoporosis will increase in the future in conjunction with the aging of the population 
(Melton et al. 1992; Ray et al. 1997; Burge et al. 2007). The disease has a major impact on 
society, it exerts physical, psychosocial, and financial consequences. Osteoporosis is 
characterized by low bone mineral density (BMD) measured by dual-energy X-ray 
absorptiometry (DXA) and a deterioration in bone quality that predisposes the individual 
to fractures even after minimal trauma (National Institutes of Health Consensus 2001). The 
slow loss of bone is often asymptomatic and often the first sign of the disease is a fracture 
(Vestergaard et al. 2005; Unnanuntana et al. 2010). The progressive increase in the fracture 
risk occurs after accelerated bone loss especially after menopause in women. There is a 
relatively high morbidity and mortality related to the fractures (Reginster and Burlet 2006).  
Peak bone mass is achieved in the age of early 20’s. This is the major determinant for the 
risk of osteoporosis later in life (Hernandez et al. 2003). Thus, the childhood and adolescent 
periods are important for bone health. Osteoporosis is caused by an imbalance in bone 
remodeling, and thus, understanding of the cellular events is important in advancing the 
treatment. BMD is a good measure of bone density but its ability to predict fractures is only 
moderate (Greenspan 2004; Pasco et al. 2006). Hence, other bone properties, especially bone 
structure, composition, and metabolism, need to be studied to understand better the factors 
contributing to bone strength, and thus, to predict fracture risk more effectively (Seeman 
and Delmas 2006).  
Bone quality is a term used to describe aspects of bone structure and composition 
independently of BMD (Compston 2006). Bone quality not only includes bone architecture, 
geometry, turnover, microdamage, and mineralization but also the composition of bone 
matrix and mineral (National Institutes of Health Consensus 2001). Bone properties are 
largely interdependent. Thus, impairment in one property leads often to another 
abnormality. Bone quality can be measured using several approaches (Compston 2006).    
Quantitative bone histomorphometry has become the standard method to evaluate 
cellular events of bone modeling and remodeling. It is a valuable and well-established 
clinical and research tool for studying the effects of treatment, etiology, and pathogenesis of 
metabolic bone diseases (Recker et al. 2011). Alterations in bone remodeling contribute to 
impaired bone microstructure (Compston 2006). A three-dimensional measure of bone 
microarchitecture using microcomputed tomography (micro-CT) provides better 
visualization of bone structures than any of the two-dimensional methods (Compston 2006; 
Recker et al. 2011). In addition to analysis of the trabecular microarchitecture, micro-CT 
enables quantification of the spatial mineral density (Entezari et al. 2012). The organic 
matrix of bone consists mainly of collagen type I that confers flexibility on the bone 
structure whereas the inorganic matrix consists of mineral crystals that provide its stiffness 
(Currey 2001). Changes in collagen cross-linking and alterations in mineral crystal size and 
structure may have biomechanical implications (Paschalis et al. 2001; Vashishth et al. 2001; 
Wang et al. 2002). Bone matrix and mineral composition can be measured using Fourier 
transform infrared spectroscopic imaging (FTIRI) (Boskey and Mendelsohn 2005).   
This study aimed to reveal the role of qualitative properties of bone beyond what can be 
determined with bone density measurements. Changes in bone quality were characterized 
by quantifying bone remodeling using bone histomorphometry in specific cohorts of adult 
and pediatric patients. This was combined with studies of the bone microarchitecture and 
composition using micro-CT and FTIRI.  
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2  Review of Literature 
2.1 BONE BIOLOGY 
The skeletal system consists of bone and cartilage. The skeleton supports and protects the 
internal organs and muscle attachment to enable locomotion. In addition to this structural 
function, the skeleton participates in crucial hormonal functions. For instance, it is 
important in the maintenance of serum homeostasis as a reserve of calcium and phosphate.  
The microstructure of bone is constantly changing in response to mechanical and hormonal 
stimuli. Bone remodeling is a process that helps to maintain optimal bone structure through 
the renewal of old structures (Buckwalter et al. 1996a; Hadjidakis and Androulakis 2006).  
2.1.1 Structure of bone 
Bone tissue is a complex structure that consists of cortical (compact) bone and cancellous 
(trabecular) bone (Seeman and Delmas 2006). The outer layer of cortical bone is called 
periosteum and the inner side is called endosteum (Buckwalter et al. 1996a). Cortical bone 
accounts for most of the skeletal mass, i.e., approximately 80% of the mature skeleton 
(Adler 2000). Fatty or hematopoietic bone marrow is not only important for the 
development of bone cells but also for the support of blood circulation in bone tissue. 
Cancellous bone is characterized by its high metabolic activity and modeling properties. 
Thus, it can respond more rapidly to changes in mechanical loading than can cortical bone 
(Buckwalter et al. 1996a). This is explained by high bone surface area (80%), originating 
from the network-like structure of cancellous bone (Adler 2000). The bone mass, however, 
is much higher in cortical bone than in cancellous bone and the porosity of the cortical bone 
has been found to be around 3-5% in young individuals (Burr 2010).         
Both cortical and cancellous bone can consist of woven (fiber or primary) or lamellar 
(secondary) bone (Sevitt 1981; Currey 1984; Buckwalter 1994). The composition, 
organization, mechanical properties, and formation differ between these structures. Woven 
bone is typically embryonic bone and it is rarely present in the healthy skeleton after the 
age of 4-5 years (Buckwalter et al. 1996a). Soft-tissue injury, therapies stimulating bone 
formation, inflammation, and some metabolic or malignant diseases may trigger the 
formation of woven bone. Woven bone is characterized by an irregular collagen structure 
and a high osteocyte volume (Buckwalter et al. 1996a). In contrast, lamellar bone is formed 
by tightly organized collagen fibrils that vary less in diameter than those found in woven 
bone (Cooper et al. 1966; Currey 1984; Martin and Burr 1989). Due to its more balanced cell 
and water content in combination with the organized collagen structure and regular 
mineralization pattern, lamellar bone is less brittle than woven bone (Seeman and Delmas 
2006). Lamellar bone forms structures of trabeculae in cancellous bone, and circumferential, 
interstitial, and osteonal lamellae (i.e., Haversian canals) in cortical bone (Buckwalter 1994).  
The vascular system in bone transports nutrients to the bone marrow, bone tissue, and 
periosteum. Disruption of the blood supply caused by a disease, injury, or operation may 
lead to tissue necrosis and impaired bone healing (Buckwalter et al. 1996a). The vascular 
system of bone consists of a complex network which is necessary to transfer systemic 
signals such as hormonal effects to and from bone.      
2.1.2 Bone cells 
Bone cells are responsible for bone formation and resorption events, taking part to retain 
the mineral homeostasis, and fracture repair. The cells have two origins. Firstly, the 
hematopoietic cell-line gives rise to circulating or marrow monocytes in addition to 
preosteoclasts and osteoclasts. Secondly, the mesenchymal stem-cell line are the origins of 
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undifferentiated cells or preosteoblasts, osteoblasts, bone lining cells, and osteocytes 
(Buckwalter et al. 1996a). 
 
Osteoclasts 
Unlike other bone cells, bone resorbing cells, osteoclasts, have a hematopoietic stem-cell 
(HSC) precursor from the monocyte/macrophage family (Teitelbaum 2011). There are two 
principal cytokines that are essential for osteoclast differentiation; receptor activator of 
nuclear factor-κB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF, also 
CSF-1) (Khosla 2001). RANKL and M-CSF are produced by marrow stromal cells, osteoblast 
lineage cells, and T cells (Pixley and Stanley 2004). RANKL is the key cytokine in 
osteoclastogenesis and in osteoclast activation (Khosla 2001); it belongs to the tumor 
necrosis factor (TNF) super family. M-CSF is important in proliferation, survival, and 
differentiation of osteoclast precursors but also in the survival and cytoskeletal 
rearrangement in bone resorption. Osteoprotegerin (OPG) is a physiological RANKL 
inhibitor, i.e., an anti-osteoclastogenic protein (Kostenuik and Shalhoub 2001) produced by 
osteoblasts (Khosla 2001).  To sum up, the RANKL-OPG ratio is the key regulator of the 
bone resorption process.   
 
 
Figure 1. Histological image of bone resorbing cells, osteoclasts. Osteoclasts are identified as 
typically multinucleated, large to giant cells that are often irregular in shape (arrow). 
Osteoclasts are able to produce a microenvironment that degrades the bone matrix. Masson 
Goldner trichrome stain. Magn. 400×.  
 
 In the differentiation process of osteoclasts, HSCs express c-Fms and receptor activator 
of nuclear factor-κB (RANK) that are receptors for M-CSF and RANKL, respectively (Ross 
2006; Mizoguchi et al. 2009). Mesenchymal stromal cells and osteoblastic lineage cells 
respond to signals that stimulate bone resorption, such as secretion of parathyroid hormone 
(PTH) and vitamin D3 (Aubin and Bonnelye 2000; Zhang et al. 2001). A multitude of pro- 
and anti-osteoclastogenic proteins, such as RANKL, M-CSF, and OPG are secreted from 
stromal and osteoblastic cells. This enhances osteoclast differentiation leading to osteoclast 
progenitor cell fusion to become mature multinucleated giant osteoclasts under the 
influence of RANKL (Khosla 2001; Matsuo et al. 2004).  
Bone resorption is the main function of osteoclasts by means of the degrading function of 
the lysosomal enzymes like tartrate-resistant acid phosphatase (TRAP) and cathepsin K 
(Väänänen et al. 2000). Osteoclasts are capable of forming a unique microenvironment that 
separates the cell from the general extracellular space (Boyle et al. 2003; Teitelbaum 2011).    
Histologically osteoclasts are identified typically as multinucleated cells that range from 
large to giant in size (Figure 1). The cell is irregular in shape and stains positively for TRAP. 
Cytoplasm is foamy and acidophilic (Hancox 1972; Malluche and Faugere 1986) containing 
a large number of mitochondria and lysosomes (Buckwalter et al. 1996a). A perimeter zone 
can be detected on the attachment site to bone surface. The fluid cavity between the cell and 
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the mineral matrix, i.e., ruffled border can be observed (Hancox 1972). On trabecular and 
periosteal bone surfaces, osteoclasts form resorption depressions called Howship’s lacunae. 
The resorption cavities in cortical bone are formed so that they follow the osteonal tunnels 
through the bone (Buckwalter et al. 1996a). 
 
Osteoblasts 
Osteoblasts constitute from mesenchymal precursor, i.e., osteo-chondrogenic precursor 
(Bianco et al. 2001). The differentiation from stem cells into mature osteoblasts has several 
phases. Mature osteoblasts account for bone formation by producing both collagenous and 
non-collagenous bone matrix at bone resorption site (Buckwalter et al. 1996a; Hadjidakis 
and Androulakis 2006). They also take part in bone mineralization (Marotti et al. 1972), and 
may play a role in electrolyte flow between extracellular and osseous fluid (Raisz and 
Kream 1983). Histologically, osteoblasts are identified as plump cells that lie in line on top 
of the unmineralized bone, osteoid (Figure 2). During the maturation process, the cells 
become less plump and lose their bone forming activity (Malluche and Faugere 1986; 
Hancox 1972).  
Osteoblast differentiation can be divided into three phases: proliferation, maturation, 
and termination. Firstly, mesenchymal stem cells (MSCs) proliferate to osteo-chondogenic 
precursors. This is followed by maturation to pre-osteoblast, immature osteoblast, and 
mature osteoblasts (Eriksen 2010). The earliest osteoblastic marker called Runt-related 
transcription factor 2 (Runx2) has an important role in the stimulation of the progenitor 
cells to differentiate into osteoblast lineage cells (Komori et al. 1997). Osteoblast 
differentiation is also modulated by several autocrine, paracrine, and endocrine factors (Qin 
et al. 2003). Several pathways interact, and the balance between activators and repressors is 
crucial for adequate cell development and maturation. Some of the main pathways include 
bone morphogenetic proteins (BMPs), growth factors such as insulin-like growth factor 1 
(IGF-1) and fibroblast growth factor (FGF), and systemic hormones like PTH (Qin et al. 
2003; Westendorf et al. 2004).     
 
Figure 2. Histological image of bone forming cells, osteoblasts. Osteoblasts are identified as 
plump cells that lie in line on top of the unmineralized bone, osteoid, producing bone matrix 
material. Masson Goldner trichrome stain. Magn. 200×. 
 
Another important regulation pathway in the osteoblast differentiation is so called 
Wingless-int, i.e., WNT signaling pathway. WNTs are glycoproteins (Eriksen 2010) that 
bind to their receptor complexes transducing their signals to β-catenin (Boyden et al. 2002; 
Little et al. 2002; Westendorf et al. 2004; Clevers 2006). WNT/β-catenin signaling is 
important in mechanotransduction, fracture repair, and osteoclast maturation (Robinson et 
al. 2006; Spencer et al. 2006; Chen et al. 2007) modulated by Runx2 and Osterix (Hill et al. 
2005). Sclerostin is an osteocyte-derived WNT antagonist (a protein) that is encoded by 
SOST gene (Balemans et al. 2001; van Bezooijen et al. 2005). Sclerostin inhibits osteoblast 
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activity (van Bezooijen et al. 2007), and a monoclonal sclerostin antibody has been found to 
have anabolic skeletal effects in humans (Padhi et al. 2011).   
Finally in the end of the bone formation cycle, the active osteoblast has three pathways to 
termination. The cells may remain on the bone surface and lose their formation activity 
thereby flattening and becoming bone lining cells. Some of the cells become surrounded by 
the matrix and become transformed into osteocytes whereas some of the cells undergo 
programmed cell death, apoptosis (Hadjidakis and Androulakis 2006).  
 
Bone lining cells 
Bone lining cells have a mesenchymal origin. Some of the osteoblasts differentiate as lining 
cells after completing bone formation (Hadjidakis and Androulakis 2006; Eriksen 2010). 
These flat cells are located in a line directly against the bone matrix on endocortical and 
cancellous bone surfaces (Bianco et al. 2001). Histologically, the lining cells are identified as 
flat and elongated cells (Hauge et al. 2001). The amount of cytoplasm and the number of 
organelles are lower than in mature osteoblasts (Buckwalter et al. 1996a).     
 
Osteocytes 
Osteocytes are non-proliferative bone cells originating from MSCs through osteoblast 
differentiation (Noble 2008; Bonewald 2011). They account for 90-95% of all bone cells in the 
skeleton (Bonewald 2011). Approximately 10-20% of the osteoblasts differentiate into 
osteocytes (Noble 2008) that can stay viable in bone for decades (Bonewald 2011). During 
osteocytogenesis, osteocytes become encased in the mineralized matrix, getting ‘buried’ in 
the bone matrix in lacunas (15-20 μm) as so called ‘osteoid osteocytes’ (Bonewald 2011). 
Osteocytes express long dendritic processes that extend through a canalicular structure 
(250-300 μm). These dendrites extend processes towards both the bone surface and blood 
vessels forming an elaborate canalicular structure with a large surface area (Bonewald 
2011). Since they have a large surface area, osteocytes are thought to be capable of reacting 
to minor changes in the bone microenvironment thereby changing expression of growth 
factors and controlling mineralization (Frost 1960; Noble 2008). Thus, they could act as 
mechanosensory cells (Bonewald 2011). The mechanism triggering osteocytes to start to 
differentiate from osteoblasts to embedded cells in osteoid is unknown (Bonewald 2011). 
Sclerostin is a marker of mature osteocytes (Poole et al. 2005) and it is known to suppress 
bone formation (Balemans et al. 2001).  
Histologically osteocytes can be identified as individual cells located in lacunae of the 
mineralized bone matrix. Osteocytes are relatively small cells with cytoplasmic processes 
that extend to narrow canaliculi forming an elaborate network. Hence, the osteocytic 
network interconnects throughout the living bone (Malluche and Faugere 1986).  
2.1.3 Bone matrix 
Bone consists of cells and matrix. The extracellular matrix (ECM) of the bone composite 
consists of mineral (50-70%), organic components (20-40%), and water (10%) (Dempster 
2006). Both organic and inorganic matrix is necessary for metabolic and mechanical 
functions (Seeman and Delmas 2006). The organic matrix is responsible for tension 
resistance (viscoelasticity and tensile strength) whereas the inorganic matrix confers other 
properties such as compression resistance and stiffness (Buckwalter et al. 1996a; Currey 
2005).  
The organic matrix contains collagens (approximately 90%), non-collagenous proteins, 
and lipids (Dempster 2006). Type I collagen accounts for approximately 90% of the entire 
collagen content (Hadjidakis and Androulakis 2006). Type I collagen can be distinguished 
from other collagen types based on its unique amino acid content (Buckwalter et al. 1996a). 
Collagen forms intermolecular cross-links in tissue initiated by enzymes (Eyre et al. 1984a; 
Eyre et al. 1984b). Seven different cross-link patterns have been characterized: 
dehydrodihydroxylysinonorleucine (deH-DHLNL), dehydrohydroxylysinonorleucine 
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(deH-HLNL), dehydrohistidinohydroxymerodesmosine (deH-HHMD), pyridinoline (Pyr), 
deoxypyridinoline (d-Pyr), pyrrole, and histidinohydroxylysinonorleucine (HHL). The first 
three cross-links are reducible by sodium borohydride (NaBH4) whereas the last four are 
non-reducible (Yamauchi 1996). With maturation, the number of DHLNL cross-links 
decreases whereas the number of Pyr cross-links increases partly due to the maturation of 
DHLNL to Pyr with time (Eyre et al. 1984b).   
The inorganic matrix accounts for the mineral phase of bone that is a nanocrystalline, i.e., 
an analog of hydroxyl apatite [Ca10(PO4)6(OH)2]. Hydroxyl apatite may have carbonate, 
magnesium, or acid phosphate substitutes (Wopenka and Pasteris 2005). Inorganic matrix 
preserves a remarkable ion reservoir to control ion (calcium, phosphate, magnesium) 
homeostasis. Additionally, it is important for determining bone mechanical stiffness and 
strength (Buckwalter et al. 1996a). With increasing tissue age, changes in the mineral 
crystals may affect bone mechanical properties (Akkus et al. 2004). Therefore, both the age 
and the amount of mineral affects bone material properties (Buckwalter et al. 1996a; Faibish 
et al. 2006).   
Water accounts for approximately 10% of the bone weight (Dempster 2006). The amount 
of water is dependent on tissue age (Robey and Boskey 2009). Lipids account for around 2% 
of the dry weight of bone. In addition, there are several growth factors (Buckwalter et al. 
1996a) and enzymes in the bone matrix of which some are cell associated and some are 
located in the ECM (Robey and Boskey 2009).  
2.1.4 Bone mineralization 
Within the bone mineralization, solid calcium phosphate is formed from calcium and 
phosphate in the organic matrix (Buckwalter et al. 1996a). This transformation is a series of 
sequential events that occurs in two phases. The mineral deposition during the remodeling 
cycle is called primary mineralization, whereas secondary mineralization occurs after 
completion of the remodeling cycle (Meunier and Boivin 1997).    
Firstly, a crystalline apatite, the early form of the calcium phosphate, is produced into 
the collagen network. Secondly, the amount of minerals increases in the hole zones 
followed by increase in their size. Hence, the mineral extends to fill the gaps between the 
holes (Glimcher 1992; Roberts et al. 1992). The mineralization increases and the crystals 
mature with time, thereby increasing the bone stiffness. Woven bone is replaced by lamellar 
bone (Torzilli et al. 1981). Bone turnover rate affects the degree of secondary mineralization. 
When the bone turnover rate is low, there is more time for the mineralization process to be 
completed in contrast to high turnover bone where removal of recently formed bone occurs 
prior to proper secondary mineralization (Meunier and Boivin 1997). If the mineralization 
fails, as is the case in osteomalacia and rickets, the high amount of unmineralized bone 
leads to increased fragility (Demiaux et al. 1992).  
2.1.5 Bone formation, growth, and bone modeling 
The formation of the skeleton starts in the embryo and continues after birth (Teti 2011). 
There are two types of bone formation: endochondral ossification and intramembranous 
ossification (Teti 2011).   Peak bone mass is achieved in early adulthood, and heritable 
factors account for 60-80% of the variation in peak bone mass (Heaney et al. 2000).   
Endochondral ossification, i.e., ossification via a cartilaginous model, accounts for the 
formation of long bones (not clavicle), short bones, and epiphyseal ossification centres. At 
epiphyseal sites, the ossification continues until the skeleton is mature. In intramembranous 
ossification, the bone formation occurs without a cartilage model (Buckwalter et al. 1996b). 
This is responsible for the embryonic development of the flat bones, frontal and parietal 
bones of the skull, and pelvis (Gentry and Bramblett 1988; Buckwalter et al. 1996b).   
Bone modeling alters bone shape and size by adapting to the mechanical loading during 
growth, whereas bone remodeling accounts for bone turnover without causing any 
alterations in the bone shape mainly after growth (Seeman 2009). The adaptation to 
mechanical forces is also known as Wolff’s law (Frost 1994). Initial ossification of the 
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embryonic skeleton requires simultaneous bone modeling and remodeling. Consequently, 
the collaboration between bone cells occurs in a specific order under multiple regulators 
(Seeman 2009). During growth, bone is removed and replaced rapidly (Buckwalter et al. 
1996b; Teti 2011). Growth of the physes allows lengthening of the bone. Metaphyseal 
reshaping is necessary for maintaining the long shape of the bone. Without this, the 
periosteal bone formation would increase the bone diameter. The endosteal resorption 
enlarges the medullary cavity. The changes are mostly due to bone modeling but some 
remodeling occurs as well (Buckwalter et al. 1996b). In bone modeling, bone formation and 
resorption occur simultaneously even for long periods and over large regions (Seeman 
2009). 
2.1.6 Bone remodeling 
Bone remodeling replaces the old damaged bone tissue with new competent bone tissue. 
The bone remodeling sites are located at cancellous bone and Haversian canal surfaces.  
The remodeling system is capable of responding to hormonal and nutritional influences as 
well as to the changing mechanical loads (Hadjidakis and Androulakis 2006). In general, if 
mechanical loads are redused as occurs during immobilization, all bone loss occurs through 
bone remodeling (Robling 2012). Bone remodeling can be differentiated into 5 stages: 1) 
quiescence, 2) activation, 3) resorption, 4) reversal, and 5) formation (Figure 3) (Seeman 
2009, Teti 2011). The sequential remodeling events occur in bone multicellular units 
(BMUs). The length of the cycle can take up to 6 months (Recker et al. 1988) of which 
around 2 weeks is required for bone resorption, 4 to 5 weeks for the reversal phase, and 
finally bone formation may last for 4 months until the new bone structural unit (BSU) is 
completed.  There are complex signaling pathways between the skeletal cells but also 
within each cell (Hadjidakis and Androulakis 2006). 
As the key requirements for bone remodeling, both bone resorption and bone formation 
have to occur at the same site in combination with quantitative balance and precise timing. 
The first stage of remodeling, quiescence, is the phase when lining cells still cover the 
mineralized bone surface. It has been postulated that the bone remodeling site is 
anatomically separated by the surrounding environment by a bone remodeling 
compartment (BRC) that is formed either by osteoblast-lineage cells (Hauge et al. 2001; 
Andersen et al. 2009; Jensen et al. 2012) or by macrophage-lineage cells (OsteoMacs) (Pettit 
et al. 2008). The BRC has been proposed to form a sealing zone that critically controls bone 
remodeling (Andersen et al. 2009).  
In the second stage, activation, osteoclast precursors are recruited into the remodeling site 
in response to multiple signals that also trigger the cells to undergo maturation (Seeman 
2009). The pathways causing osteoclast recruitment before osteoclastogenesis are a topic of 
intense research (Teti 2011). Sphingosine-1-phosphate (S1P) and several other factors such 
as chemokines co-operate in osteoclast recruitment (Yu et al. 2003; Yu et al. 2004; Kim et al. 
2005; Ishii et al. 2011). In addition, osteocyte apoptosis seems to trigger osteoclast activation 
although the exact details remain unclear (Verborgt et al. 2002). However, the osteoblast 
lineage cells secrete enzymes that digest the bone surface and express RANKL that is a 
member of the TNF superfamily. RANKL interacts with its receptor RANK on the surface 
of osteoclast precursors. These events then activate osteoclast differentiation and activation 
(Hsu et al. 1999). The effects of RANKL can be inhibited by OPG that is a glycoprotein 
belonging to the TNF superfamily and which is secreted mainly by osteoblast lineage cells 
(Simonet et al. 1997; Hofbauer and Schoppet 2004). OPG is a soluble receptor that acts as an 
antagonist for RANKL. It regulates bone resorption by inducing osteoclast apoptosis but 
also inhibits the final differentiation and activation. The effects of OPG are fully reversible 
(Hadjidakis and Androulakis 2006).  
The third stage of remodeling, the resorption phase, is a short phase lasting for only from a 
few days to around two weeks. During the resorption phase, osteoclasts mature, polarize, 
adhere to the bone surface, and degrade the bone matrix (Recker 1988; Teti 2011). The 
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completion of resorption phase is caused by multiple signals that trigger osteoclast 
apoptosis (Del Fattore et al. 2008). However, the balance between pro-apoptotic and anti-
apoptotic factors is crucial because the M-CSF and RANK/RANKL systems can intervene 
during extended osteoclast survival (George et al. 2010). As a results of osteoclast death, the 
remodeling site becomes free of osteoclasts (Del Fattore et al. 2008).  
The next stage in the remodeling, reversal, is not fully understood. The cells involved and 
the biological importance of this stage are unknown, but typically macrophage-like 
mononuclear cells are thought to be involved. This might be a consequence of collagen 
degradation or to debris removal (Teti 2011). Additionally, proteoglycans, similar to those 
on the cement line, have been found at sites where the osteoclast activity has been reduced 
after the resorption phase suggesting that these reversal cells could contribute to the cement 
line cells. Further, the aim of the reversal cells could also be to stimulate the completion of 
the remodeling cycle (Raisz 1999).  
 
 
Figure 3. A bone remodeling site. The osteoblast precursors expressing RANKL on their surfaces 
interact with their receptor RANK on the osteoclast precursors. This enhances maturation and 
activation of the osteoclasts. After resorption of old bone by osteoclasts, the new bone matrix, 
osteoid, is formed by osteoblasts. Reprinted with the kind permission by Springer from Rauch 
2006.  
 
The last stage of remodeling cycle is the bone matrix formation (Hadjidakis and 
Androulakis 2006; Seeman 2009). Osteoblast precursors mature at the resorption site. The 
formation phase occurs slowly requiring 3 to 4 months before completion (Pevsner-Fischer 
et al. 2011). During this time, new unmineralized bone, osteoid, is formed and later 
mineralized (Hadjidakis and Androulakis 2006). The mechanisms involved in the 
recruitment of osteoblast precursors to the remodeling site are under investigation (Teti 
2011). Osteoclasts could send signals to osteoblasts but also osteocytes are thought to co-
ordinate the bone remodeling (Khosla 2001; Hofbauer and Schoppet 2004; Bonewald 2011). 
Several signals may interact to complete the formation phase (Teti 2011).   Osteocytes have 
been believed to emit signals after they become trapped in the mineral matrix. Sclerostin 
has been thought to be one of the major factors accountable for this phenomenon. It is 
secreted by osteocytes and it blocks WNT signaling thereby blocking osteoblast induction 
(Moester et al. 2010). At the end of the formation phase in the healthy skeleton, 
approximately 5% of additional bone compared to resorption is formed in every 
remodeling cycle (Parfitt et al. 2000). After the fifth decade of life and in some metabolic 
bone diseases such as osteoporosis, the bone formation decreases with respect to bone 
resorption, leading to bone loss (Parfitt et al. 2000; Rachner et al. 2011). Further, altered 
mineralization may occur in metabolic bone disease such as in vitamin D deficiency 
(Demiaux et al. 1992).  
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2.1.7 Regulators of bone  
Our understanding of the mechanisms controlling bone-cell activity and crosstalk has 
increased rapidly during the last years but many functions still remain a mystery. The 
discovery of the RANK/RANKL/OPG-pathway has increased the appreciation of the 
importance of regulatory factors (Khosla 2001). Several systemic and local factors, including 
genetic factors, systemic hormones, exercise, obesity, and local factors e.g. cytokines and 
prostaglandins, contribute to the regulation of the bone-cells and to the interactions 
between cells (Buckwalter et al. 1996b; Hadjidakis and Androulakis 2006).  
 
Hereditability and local factors 
The hereditability related to skeletal size with regards to height and other anthropometric 
variables has known for decades (Clark 1956). Genetic factors regulate peak bone mass and 
approximately 80% of the bone mass has been considered to be regulated by genes (Smith 
et al. 1973; Howard et al. 1998; Peacock et al. 2002). Genetic factors are associated with 
many bone diseases, for example osteogenesis imperfecta (OI) (Peacock et al. 2002; Rauch 
and Glorieux 2004). However, the hereditability of bone loss in advanced age is low 
(Moayyari et al. 2012). Similarly, the hereditability of fractures in the oldest age is low 
(Kannus et al. 1999; Michaëlsson et al. 2005).  
Cytokines and prostaglandins exert direct effects on bone-cell activity (Buckwalter et al. 
1996b). Several in vitro studies support the theory that cytokines, such as TNF-α and 
interleukin-10 (IL-10), affect bone metabolism including bone remodeling (Hofbauer and 
Schoppet 2004). Prostaglandins, which are fatty acid derivates, may have a local effect on 
bone cells, modulating cellular events e.g. inflammation and ion transport in other tissues 
(Buckwalter et al. 1996b).  
 
Hormones 
Systemic hormones mediate their effects throughout the skeleton and regulation of calcium 
homeostasis is one of their main functions. Nowadays, it is appreciated that the metabolic 
function of bone is an extremely vital phenomenon (Guntur and Rosen 2012).  
PTH is a hormone secreted by the chief cells of the parathyroid gland. PTH is secreted in 
conditions of hypocalcaemia to ensure a normal serum calcium level (Figure 4).  There is an 
integrated interaction between calcium regulation and phosphate metabolism. A high 
serum phosphate level stimulates PTH production because phosphate binds to free calcium 
thus leading to a reduction in the serum calcium level (Silver and Naveh-Many 2009). As a 
result of the elevated serum concentration of phosphate, FGF-23 is secreted from 
osteoblasts and osteocytes which leads to suppressed reabsorption of the phosphate in the 
kidneys (Fukumoto 2008). It has been speculated that FGF-23 could be a target for novel 
therapies (Shimada and Fukumoto 2012). 
Calcitonin is a hormone that decreases serum calcium level. The C cells of the thyroid 
gland secrete this hormone. Calcitonin has been claimed to inhibit osteoclasts either by 
attenuating osteoclasts differentiation or by suppressing bone formation and activation of 
osteoclasts (Copp and Cameron 1961; Nicholson et al. 1986). The effects of calcitonin are 
very short-term, and its role for healthy bone physiology is unclear (Buckwalter et al. 
1996b).  
Age and sexual maturity affect the secretion of several systemic hormones that also 
regulate bone growth (Teti 2011). Before puberty, growth hormone stimulates pubertal 
bone growth thereby increasing the bone mass (Wang et al. 2004). Thyroid hormones have 
been shown to have a positive effect on skeletal growth due to increased energy production 
(Gogakos et al. 2010).   
Estrogens, secreted from ovaries, have actions on PTH, calcitonin, and vitamin D thereby 
increasing calcium reabsorption in the kidney (Buckwalter et al. 1996b). Both osteoblasts 
and osteoclasts possess estrogen receptors. Estrogen deprivation, as occurs after 
menopause, accelerates bone loss in women due to increased remodeling activity and a 
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more negative bone multicellular unit (BMU) balance.  The lifespan of osteoblasts is 
reduced whereas the lifespan of osteoclasts is prolonged. Further, the mineral content of 
bone decreases due to the high remodeling rate (Seeman 2003).    
 
 
Figure 4. Regulation of calcium metabolism. In hypocalcaemia, parathyroid hormone (PTH) 
stimulates the release of calcium from bone, increases the reabsorption of calcium in the renal 
tubules, and also affects indirectly the reabsorption of calcium in the intestine by increasing the 
synthesis of calcitriol in the proximal tubules of kidneys to maintain normocalcaemia (Potts 
2005). The regulation of phosphate metabolism is interrelated (Silver and Naveh-Many 2009). 
The increased phosphate level of blood stimulates production of FGF-23. This leads to decreased 
reabsorption of phosphorus in the kidneys (Fukumoto 2008). P=plasma, 1,25-OHD=1,25-
dihydroxyvitamin D (calcitriol). Modified from Holick (2007) and Fukumoto (2008).  
 
Vitamin D and calcium 
Both vitamin D and calcium are vital for bone metabolism. Production of vitamin D3 
(cholecalsiferol) from the 7-dehydrocholesterol is promoted by ultraviolet B radiation in the 
skin. Calcium and vitamin D can also be obtained from food. Vitamin D3 is further 
metabolized in the liver to 25-hydroxyvitamin D (25-OHD, calcidiol). The biologically 
active metabolite, 1,25-dihydroxyvitamin D (1,25-(OH)2D, calcitriol), is formed by 
hydroxylation from calcidiol in the kidneys (DeLuca 2004; Holick 2006; Holick 2007). The 
effects of calcitriol on bone are complex. Calcitriol increases the serum concentration of 
calcium and phosphorus, and stimulates the absorption of calcium in the intestine. 
Although osteoclasts do not possess vitamin D receptors (VDR) (Yasuda et al. 1998), the 
increase in the serum concentration of calcium and phosphorus is mediated by the 
increased formation of osteoclasts by the activated RANK/RANKL pathway through 
osteoblasts (Raisz et al. 1972; Holick 2007). In contrast, calcitriol downregulates OPG 
production therefore stimulating osteoblast formation (Yasuda et al. 1998). Thus, calcitriol 
stimulates also mineralization of the bone matrix (Holick 2007).  
PTH is the main stimulator of the production of calcitriol in the kidneys. There is a 
feedback mechanism through which calcitriol inhibits the synthesis and secretion of PTH 
(Martin and Gonzalez 2004). Low levels of serum phosphate, calcium, or FGF-23 and 
increased PTH level favor production of calcitriol (Holick 2007).    
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Mechanical loading 
Previous studies have revealed that moderate regular physical exercise can help to 
maintain bone mass not only in young subjects but also in the elderly (Rubin et al. 1990; 
Callreus et al. 2012; Korhonen et al. 2012), or at least to decelerate bone loss in elderly 
(Rubin et al. 1992; Rikkonen et al. 2010). Regular exercise in children and adolescents 
improves gain in bone mass (Pitukcheewanont et al. 2010). Age and hormonal balance may 
change the responses of bone to mechanical loading (Bain and Rubin 1990).   
2.2 BONE QUALITY 
Bone density accounts for only 70% of bone strength but there are currently no better 
measures available for clinical practice (National Institutes of Health Consensus 2001). Bone 
strength can be defined by the composition and structure of bone material (Currey 2001). 
Bone has to be stiff in order to resist deformation, and thereby, to be able to resist fractures. 
In addition, bone must absorb energy and respond to forces with appropriate flexibility. 
Furthermore, the weight of bone should be light enough to enable locomotion. Therefore, 
numerous aspects of bone material and structural properties account for bone health  
(Seeman and Delmas 2006) and are able to respond to the bone’s mechanical needs (Currey 
2005). 
Currently, the definition of osteoporosis includes both loss of bone mass and alteration 
in bone quality (National Institutes of Health Consensus 2001). Bone quality is the term 
used to describe aspects of bone structure and composition independently of BMD 
(Compston 2006). Bone quality includes bone architecture, geometry, turnover, 
microdamage, and mineralization but also there are components reflecting the composition 
of the bone matrix and mineral  (National Institutes of Health Consensus 2001). Several 
techniques to measure bone quality have been developed to understand the pathogenesis of 
bone disease in more detail, to evaluate the effects of treatments, and especially to develop 
new therapeutic agents (Compston 2006).    
2.2.1 Assessment of bone quality 
Bone properties are strongly interdependent. Thus, an imbalance in one function typically 
leads to another abnormality. Bone quality can be measured using various approaches 
depending on the research question under investigation (Figure 5). Most of the techniques 
require a biopsy or an autopsy specimen, and are currently available only for research 
purposes. The improvements in research techniques have enhanced the understanding of 
the mechanisms that contribute to compromised bone strength, and thus to the mechanisms 
that can be targeted by therapeutic intervention (Compston 2006). 
Bone turnover can be determined in vivo using biochemical bone turnover markers. 
These markers include osteocalcin, bone specific alkaline phosphatase, procollagen type I N 
propeptide (P1NP), C-terminal telopeptide of type I collagen (1CTP), and tartrate-resistant 
acid phosphatase type 5b (TRAP-5b). The markers are mainly serum-based, and therefore, 
reflect the turnover rate in the whole body. Hence, the information obtained mirrors more 
carefully changes in cortical bone due to higher proportion of the total skeleton 
(approximately 80-90%). Several factors, such as diet, intra- and inter-individual variation, 
and sampling time, can affect the results (Compston 2006). Quantitative histomorphometry 
of bone sections can provide information on bone volume and bone remodeling activity, 
e.g., cells, osteoid formation, resorption and mineralization (Compston 2004), but a bone 
biopsy is required for this kind of analysis. Bone histomorphometry will be discussed more 
in detail below (Chapter 2.2.2). New methods for measuring bone turnover have been 
developed. It has been claimed that the regional turnover rate can be measured by using 
technetium labeled bisphosphonates (BPs) detected by single photon emission computed 
tomography (SPECT) imaging (Compston 2006). 
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Bone microarchitecture can be analysed in two-dimensions by using quantitative 
histomorphometry (Parfitt et al. 1983) or in three dimensions by using high-resolution 
micro-CT (HR-CT), high-resolution magnetic resonance imaging (HR-MRI), and peripheral 
quantitative computed tomography (pQCT) (Järvinen et al. 2005; Entezari et al. 2012). The 
three-dimensional approaches provide better visualization of bone structures than the two-
dimensional methods (Compston 2006; Recker et al. 2011).   
 
 
Figure 5. Assessment of different bone quality aspects using the various available techniques. 
Modified from Compston (2006). DXA = dual-energy X-ray absorptiometry, QCT = quantitative 
computed tomography, μCT = microcomputed tomography, HR-CT = high-resolution computed 
tomography, HR-MRI = high-resolution magnetic resonance imaging, qBEI = quantitative 
backscattered electron imaging, SAXS = small angle X-ray scattering, FTIRI = Fourier transform 
infrared spectroscopic imaging, TEM = transmission electron microscopy. 
 
Bone mineralization can be quantified in several ways such as quantitative backscattered 
electron imaging (qBEI) and spectroscopic techniques. BMD measurements are able to 
detect the degree of mineralization. Mineralization of bone is biphasic, and especially the 
second phase, i.e., accumulation of mineral matrix after completed remodeling cycle, is 
highly dependent on bone turnover. In high turnover bone, the newly formed bone is 
removed even prior to the second phase of mineralization whereas prolonged 
mineralization occurs in low turnover bone (Compston 2006).  
Bone matrix and mineral composition has been evaluated using variety of methods. 
Raman spectroscopy or FTIRI, transmission electron microscopy (TEM), or small angle X-
ray scattering (SAXS) have been used for defining organic and inorganic composition of 
bone. However, only little is known about how the alterations in bone composition affect 
bone strength.  
 
 
 
14 
Histological techniques, including confocal and fluorescence microscopy, are used to 
detect microdamage, i.e., microcracks and microfractures, in bone. The amount of 
microdamage increases with age but its contribution to bone strength remains unclear (Burr 
2002).   
2.2.2 Bone histomorphometry 
By developing a new technique to study unmineralized bone sections in the 1950s, the 
understanding of bone physiology accelerated. Prior to that, bone mineral had to be 
removed for the histological bone analysis (Recker et al. 2011). In the 1960s, Frost presented 
a new technique to measure bone formation using tetracycline labeling (Frost et al. 1960; 
Frost 1969). In 1987, the nomenclature, symbols, and units were standardized (Parfitt et al. 
1987) and later updated (Dempster et al. 2013). Consequently, quantitative bone 
histomorphometry has become the standard method to evaluate cellular events of bone 
modeling and remodeling and it is a valuable and well-established clinical and research 
tool for studying the effects of treatment, etiology, and pathogenesis of metabolic bone 
diseases (Recker et al. 2011). Unfortunately, bone histomorphometry at one site, i.e., usually 
at the iliac crest, may not reflect changes in the whole skeleton since the turnover between 
the sites may vary (Eventov et al. 1991). In addition, due to differences in the technique 
together with variation in the remodeling activity even within one sample, relatively high 
inter- and intraobserver variations have been reported (de Vernejoul et al. 1981; 
Chavassieux et al. 1985; Compston et al. 1986; Wright et al. 1992). 
 
Table 1. Some clinical situations in which bone histomorphometry may be useful (Alhava and 
Kröger 2002; Barger-Lux and Recker 2002; Trueba et al. 2003; Compston 2004; Recker 2005). 
 
Clinical situation 
Suspicion of metabolic bone disease 
Osteomalacia 
Renal osteodystrophy 
Hyperparathyroidism 
Increased bone resorption and bone loss 
Osteosclerosis 
Paget disease 
Unexplained hypophosphataemia or hyperphosphataemia 
Difficult osteoporosis 
Management plan and follow-up 
Vague bone pain 
Unknown increase of bone specific alkaline phosphatase 
Delayed bone healing after fracture 
Low energy fractures in young patients 
Atypical stress fractures in adults 
Evaluation of bone specific therapies 
 
Indications for bone biopsy 
Bone biopsy is required for the histomorphometric analysis, and because of this, the 
information gained should be greater than the risk and discomfort to the patient, or the 
financial cost of the procedure. Bone histomorphometry can be used to establish diagnosis, 
estimate prognosis, or to evaluate response or adherence to treatment (Table 1). 
Furthermore, bone histomorphometry remains important in research since all new bone 
specific drugs should be tested using bone histomorphometry (Compston 2004; Recker 
2005).  
 
Bone biopsy 
Prior to the biopsy, the bone is labeled in vivo using a fluorescent agent to study bone 
mineralization rate and bone formation. Labeling is currently performed using antibiotics 
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from the tetracycline family due to their adherence to forming bone surfaces, nontoxicity, 
and spontaneous fluorescence. Tetracycline fluorescence is light yellow, and optionally 
democycline, which emits a yellow-orange fluorescence, can be used. Patients with 
malabsorption syndrome may require a higher dose than the average. A double-labeling 
technique provides the optimal result, and thus, tetracycline is given in two courses (each 2 
days) having a period of time between the regimen courses (usually 10 days).  Bone biopsy 
is usually taken four days after the last dose of antibiotic (Trueba et al. 2003, Rauch 2009).  
The anterior iliac crest is the site most frequently used for the biopsy specimen. If 
anterior iliac crest is not accessible, e.g., because of obesity, the posterior iliac crest 
immediately lateral to the sacral-iliac joint can be used (Trueba et al. 2003). Bone biopsy 
procedure can be performed either using outpatient surgery and local anesthetic agents 
(Hodgson et al. 1986) or day-surgery setting and general anesthesia (Trueba et al. 2003). The 
patient is placed in the supine position and a local anesthetic agent such as lidocaine is 
infiltrated around the biopsy site including the periosteum. The biopsy site is supported by 
the finger and a short longitudinal incision of 0.5-1 cm is made using a scalpel over the 
anterior iliac crest. Blunt dissection is used to achieve the correct biopsy site. Bone biopsy 
can be taken using either vertical or horizontal (i.e., through-and-through) technique. 
Vertical biopsy is taken by approaching the iliac crest superiorly and alongside the iliac 
crest so that only one cortex is included whereas the horizontal biopsy is taken through the 
iliac crest such that both cortices are included. Because of the iliac crest growth plate, the 
vertical approach should not be used in children (Rauch 2009). It is recommended that the 
investigator should use a funnel and electric drill when taking the specimen (Trueba et al. 
2003). Bone biopsy needle set needed in the biopsy procedure is illustrated in Figure 6.  
The sample should be carefully removed from the drill and placed in 70% ethanol 
solution (Hodgson et al. 1986; Recker 2008). A biopsy trephine with an inner diameter of at 
least 7.5 mm is recommended for adults and a smaller one with inner diameter of 5 mm for 
children (Dempster et al. 2013). If needed, 1-2 attempts can be made to obtain a proper 
specimen (Hodgson et al. 1986). The bony defect(s) are packed with sterile medical wax to 
minimize bleeding and prevent hematoma formation and the incision is closed in two 
layers. The total time required for the surgical procedure is usually 10-15 minutes. 
Appropriate wound care is necessary in order to avoid postoperative wound infections 
(Trueba et al. 2003).  
 
Figure 6. The equipment needed for bone biopsy. From left: guide sleeve, trephine cutter, 
pointed obturator, and extractor (Medical Innovations International Inc., Rochester Bone 
Biopsy). 
 
Complications after bone biopsy 
Bone histomorphometry is considered to be a fairly safe method due to the low 
complication rate after the biopsy. Duncan et al. (1981) studied over 14,000 biopsies that 
were taken by numerous physicians using various biopsy techniques. The complication rate 
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was as low as 0.52% showing a higher rate of 0.63% for the horizontal approach compared 
to 0.36% for the vertical approach. The most common complications encountered were 
hemorrhage (in 35 patients), prolonged pain for over a week (in 17 patients), neuropathy (in 
13 patients), wound infection (in 10 patients), fracture (in 6 patients), and osteomyelitis (in 1 
patient) (Duncan et al. 1981). In contrast, Hodgson et al. (1986) showed that even severe 
pain was frequently suffered at the time of the biopsy (24% of the 76 patients) and 16 hours 
after the biopsy (8%). Seven days after the biopsy, almost 80% of the patients experienced 
no or mild pain whereas 9% of the patients still considered the pain being as severe.  There 
were no major infections, and hemostasis was easily achieved for all patients (Hodgson et 
al. 1986).  
 
Sample preparation 
In the laboratory, the bone biopsy is prepared for the analysis through several steps: 
fixation, dehydration, embedding, sectioning, and staining. First, the biopsy is fixed in 
ethanol for 24-48 hours depending on the size of the sample. Then, the sample is 
dehydrated using increasing concentrations of ethanol because the embedding medium is 
not miscible with water. Further, the sample is embedded in methylmetacrylate (MMA). 
MMA is a non-toxic media, which penetrates into the sample quickly, and rarely evokes 
any artifacts such as bubbles. Prior to sectioning, the embedding medium should harden 
slowly, which can take up to a month. Then, a microtome is used to section the sample, and 
the sections are further stained. Different stains can be used depending on the investigation 
of interest (Trueba et al. 2003).  
 
Quantitative histological analysis 
Histological sections can be analyzed under bright light, polarized light, and fluorescence 
microscopy using automatic or semi-automatic software. The nomenclature, symbols, and 
units were standardized in 1987 by a committee of American Society for Bone and Mineral 
Research (ASBMR) (Parfitt et al. 1987) and later updated (Dempster et al. 2013). Based on 
primary parameters that can be quantified, several indices can be derived (Table 2). 
Parameters can be divided into four main categories: structural, static erosion, static 
formation, and dynamic formation variables (Rauch 2009). Quantitative results can be 
compared to reference values defined for healthy individuals in different age groups and 
races. However, for obvious ethical reasons only limited data is available especially for 
dynamic variables. Recker et al. (1988) have studied histomorphometric findings in healthy 
postmenopausal women (Recker et al. 1988). Rehman et al. (1994) have reported data in 
different age groups of both genders but because part of the study consisted of cadaver 
material, fewer cases could be included into the dynamic analysis (Rehman et al. 1994). 
Glorieux et al. (2000) have reported normative data in growing children in different age 
groups (Glorieux et al. 2000). Malluche et al. (1982) have also presented normal data but the 
terminology used differs somewhat from the later recommendations, and thus, the 
comparisons are complicated (Malluche et al. 1982). The Finnish reference values by Hoikka 
and Arnala have also been published and these included static histomorphometry data 
only (Hoikka and Arnala 1981). 
To conclude, quantitative bone histomorphometry has developed remarkably during the 
last decades. The technique is only minimally invasive, and important information about 
bone remodeling activity and metabolism can be achieved in clinically challenging 
situations. As the gold standard, prior to development of a noninvasive method which 
would provide the same information, bone histomorphometry is a valuable and well-
established clinical and research tool for evaluating the effects of treatment, etiology, and 
pathogenesis of metabolic bone diseases (Compston 2004; Recker 2005; Dempster et al. 
2013). 
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Table 2. Frequently used bone histomorphometry parameters and their interpretation. Modified 
from Rauch (2009), Recker et al. (2011), and Dempster et al. (2013).  
 
Variable Symbol Unit Equation Definition 
STRUCTURAL PARAMETERS 
Bone volume BV/TV % B.Ar/T.Ar 
Percent of marrow space occupied by 
mineralized and unmineralized bone 
Trabecular thickness Tb.Th μm 2/(BS/BV) (plate referent) Average thickness of trabeculae 
Trabecular number Tb.N N/mm (BV/TV)/Tb.Th Number of trabecular silhouettes 
Trabecular separation Tb.Sp μm (1/Tb.N)-Tb.Th Average distance between trabeculae 
STATIC EROSION PARAMETERS 
Eroded (resorptive) 
surface ES/BS % (E.Pm/B.Pm)*100 
Percent of bone surface presenting 
resorption surface 
 
Osteoclast surface Oc.S/BS % (Oc.Pm/B.Pm)*100 
Percent of bone surface occupied by 
osteoclasts 
STATIC FORMATION PARAMETERS 
Osteoid volume OV/BV % (O.Ar/B.Ar)*100 
Percent of bone volume consisting of 
unmineralized bone, i.e., osteoid 
Osteoid surface OS/BS % (O.Pm/B.Pm)*100 
Percent of bone surface covered by 
osteoid 
Osteoid thickness O.Th μm (π*O.Wi)/(4*N.O.Wi) Average thickness of osteoid seams 
Osteoblast surface Ob.S/BS % (Ob.Pm/B.Pm)*100 
Percent of bone surface occupied by 
osteoblasts 
Wall thickness W.Th μm (π*W.Wi)/(4*N.W.Wi) 
Average thickness of bone tissue that 
has been deposited at a remodeling 
site 
DYNAMIC FORMATION PARAMETERS 
Mineralizing surface MS/BS % [(dLS+½*sLS)/BS]*100 
Percent of bone surface showing 
mineralizing activity 
Mineralizing surface MS/OS % [(dLS+½*sLS)/OS]*100 Percent of osteoid surface mineralizing 
Mineral apposition 
rate MAR μm/d Ir.L.Th/Ir.L.t 
Distance between the two tetracycline 
courses divided by the length of the 
labeling interval 
Mineralization lag 
time Mlt d O.Th/Aj.AR 
Time interval between deposition and 
mineralization of bone matrix 
Bone formation rate 
(bone surface ref.) BFR/BS 
μm3/μm
2/year MAR*(MS/BS)*365.25 
Amount of bone formed per year on a 
given bone surface 
Activation frequency Ac.F N/year [(BFR/BS)/W.Th]*0.001 
Frequency of appearance of new 
remodeling units at one location per 
year 
 
B.Ar = bone area, T.Ar = tissue area, N = number, E.Pm = erosion perimeter, B.Pm = bone perimeter, Oc.Pm = 
osteoclastic perimeter, O.Ar = osteoid area, O.Pm = osteoid perimeter, π = an estimate for certain parameters (Parfitt et 
al. 1987), O.Wi = osteoid width, N.O.Wi = number of measured osteoid widths, Ob.Pm = osteoblast perimeter, W.Wi = 
wall width, N.W.Wi = number of measured lamellar structures, dLS = double labeled surface, sLS = single labeled 
surface, BS = bone surface, OS = osteoid surface, d = day, Ir.L.Th = interlabel thickness, Ir.L.t = interlabel time, Aj.AR = 
adjusted apposition rate = MAR*MS/OS 
2.2.3 Microcomputed tomography 
High-resolution micro-CT enables three-dimensional analysis of trabecular micro-
architecture and quantification of spatial mineral density of bone samples. The accuracy of 
micro-CT depends on the image resolution. Studies have shown that high resolution (10-20 
m voxel size) is necessary to accurately quantify the trabecular micro-architecture (Muller 
2003; Isaksson et al. 2011; Entezari et al. 2012). Micro-CT has been used for detecting 
structural changes in bone (Uchiyama et al. 1997). It has also been used to assess the effects 
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of therapeutic agents such as bisphosphonates (Borah et al. 2004; Recker et al. 2005). In vivo 
high-resolution micro-CT is also commercially available, but so far only for use with small 
animals (Campbell et al. 2008). 
Bone strength in cortical bone is mainly determined by cortical width, cortical porosity, 
and bone size. In cancellous bone, the main determinants of bone strength are the size and 
orientation of trabeculae together with the trabecular connectivity and orientation 
(anisotropy) (Compston 2006). In addition to the analysis of the trabecular 
microarchitecture, micro-CT enables quantification of the spatial mineral density (Entezari 
et al. 2012). Alterations in bone remodeling contribute to impaired bone microstructure 
(Compston 2006).  
2.2.4 Fourier transform infrared spectroscopic imaging 
Fourier transform infrared spectroscopy imaging (FTIRI) can be used to study the chemical 
composition of bone. The vibrations of the chemical bonds of the specimen are excited by 
incident light to visualize mineral and protein components of bone.  Bone composition can 
be analyzed based on characteristic frequencies that correspond to absorption peaks on an 
infrared spectrum (Carden and Morris 2000; Boskey and Mendelsohn 2005).  
The organic matrix of bone consists mainly of collagen type I that provides flexibility for 
bone structure. The inorganic matrix consists of mineral crystals that provide the necessary 
tissue stiffness (Figure 7) (Currey 2001). Thus, changes in collagen cross-linking and 
alterations in mineral crystal size and structure may have biomechanical implications 
(Paschalis et al. 2001; Vashishth et al. 2001; Wang et al. 2002). 
Figure 7. Fourier transform infrared spectroscopic imaging (FTIRI). The organic matrix of bone 
consists mainly of collagen type I that can be estimated by amide I peak C spectrum. The 
inorganic matrix is estimated by using the phosphate and carbonate peaks in FTIRI.  
2.3 METABOLIC BONE DISORDERS 
2.3.1 Osteoporosis 
Osteoporosis has emerged as a health concern in all age groups. However, the disease is 
most common in white postmenopausal women. Osteoporosis is characterized by low bone 
mass measured by DXA and changes in bone quality that predispose individuals to 
fractures even after minimal trauma (National Institutes of Health Consensus 2001). There 
is a relatively high morbidity and mortality related to the fractures. Due to the advancing 
age of the population, the annual incidence of osteoporotic fractures and costs have been 
estimated to rise 50% by the year 2025 (Burge et al. 2007).  
Peak bone mass, achieved in an individual’s early 20’s, is the major determinant for the 
risk of osteoporosis later in life (Hernandez et al. 2003). Thus, childhood and adolescence 
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are important for general bone health. Most importantly, osteoporosis is largely 
preventable due to the evolving understanding of the causes of the disease, and thus, the 
diagnosis and treatment of the disease have improved during the last decades (National 
Institutes of Health Consensus 2001). Osteoporosis is attributable to an imbalance in bone 
remodeling, and thus, the understanding of the cellular events is important to target the 
treatment.  
 
2.3.1.1 Pathophysiology of osteoporosis 
The compromised bone strength, as defined by decreased BMD measured by DXA and 
deterioration of bone quality, i.e., architecture, turnover, damage accumulation such as 
microdamage, and mineralization, predisposes individuals for fractures (National Institutes 
of Health Consensus 2001). After the fifth decade of life and in some metabolic bone 
diseases like osteoporosis, the bone formation decreases more than bone resorption, leading 
to bone loss (Parfitt et al. 2000; Rachner et al. 2011). Activation of the RANK-RANKL 
pathway, most commonly due to estrogen deficiency, leads to increased osteoclast activity 
that is further associated with increased bone resorption (Rachner et al. 2011). The 
progressive increase in the fracture risk occurs after accelerated bone loss especially in 
women after menopause. However, it is notable that individuals with compromised peak 
bone mass are more susceptible to develop osteoporosis even without accelerated bone loss 
(National Institutes of Health Consensus 2001).  The cellular events play an important role 
in the pathogenesis of osteoporosis, and various signals mediated via the endocrinal, 
neuroendocrinal, inflammatory, and mechanical systems have been characterized (Rachner 
et al. 2011). In addition, genes seem to intervene with environmental factors (Ferrari et al. 
1999) but also with some nutrients (Chevalley et al. 2008). 
 
Table 3. The risk factors and/or causes of osteoporosis. Modified from Moulds et al. (2001) and 
National Institutes of Health Consensus (2001). BMI = body mass index. 
 
Genetic 
and non-
modifiable 
Female 
Aging 
Thin build: low BMI <18 
Race: Asian, Caucasian 
Family history: Maternal hip fracture <75 years 
Premenopausal estrogen deficiency, e.g. amenorrhea 
Late menarche  
Early menopause <45 years (natural or surgical) 
Lifestyle 
factors 
Cigarette smoking 
High caffeine intake >4 cups a day 
Alcoholism and high alcohol intake >2 standard drinks a day 
Low calcium intake 
Lack of vitamin D or vitamin D deficiency 
Physical inactivity 
Medical 
causes 
Eating disorders, especially anorexia nervosa 
Malabsorption syndrome, e.g. celiac disease, inflammatory bowel disease 
Endocrine disorders: Cushing syndrome, diabetes mellitus, 
hyperparathyroidism, thyrotoxicosis, hypogonadism or sex hormone deficiency, 
acromegaly  
Connective tissue disorders, e.g. rheumatoid arthritis 
Inherited disorders of collagen metabolism, e.g. osteogenesis imperfecta 
Chronic organ failure, transplantation 
Iatrogenic causes: Corticosteroids, anti-epileptic drugs, thiazolidinediones, 
long-term heparin, excessive thyroid hormone, prostate cancer hormone 
therapy, breast cancer hormone therapy 
Prolonged immobilization 
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There are both primary and secondary causes for osteoporosis. Primary osteoporosis is 
most common in women after menopause due to the loss of estrogen but it can occur in 
both males and females at any age. Secondary osteoporosis, however, is caused by 
previously used medication such as the glucocorticoids (GCs), some diseases such as celiac 
disease, or other conditions (e.g. hypogonadism). Secondary causes account for 30-60% of 
osteoporosis in men and for over 50% of osteoporosis in perimenopausal women (National 
Institutes of Health Consensus 2001). There are several risk factors for osteoporosis (Table 
3). Vitamin D deficiency is common all over the world and it also causes many extra-
skeletal adverse effects, such as cardiovascular and metabolic diseases, malignancies, and 
predisposes individuals to falls (Holick 2007). 
 
2.3.1.2 Diagnosis of osteoporosis 
The diagnosis of osteoporosis is currently based on the measurement of BMD at the hip or 
lumbar spine using DXA. BMD accounts for approximately 70% of bone strength, however, 
there are currently no better measures available for clinical practice (National Institutes of 
Health Consensus 2001). The BMD value is converted to a T-score. According to the criteria 
devised by the World Health Organization (WHO), osteoporosis is defined as a BMD of 2.5 
standard deviation units below the mean of young white adult women (T-score) (Table 4). 
Osteopenia is defined as a BMD T-score between -1.0 and -2.5 standard deviations (WHO 
1994; Kanis et al. 2013). In addition, newer techniques such as quantitative ultrasound 
(QUS) have been introduced in the measurement of bone properties. Compared to DXA, 
QUS of the heel has been shown to predict both vertebral and non-vertebral fracture almost 
as well as DXA of the hip (National Institutes of Health Consensus 2001), and might 
improve the early diagnosis of osteoporosis (Liu et al. 2012).  
 
Table 4. Interpretation of bone mineral density (BMD) T-scores according to WHO criteria (WHO 
1994).  
 
BMD T-score Interpretation 
≥ -1.0 Normal 
-1.0 to -2.5 Osteopenia 
≤ - 2.5 Osteoporosis 
< -2.5 with fracture Severe osteoporosis 
 
2.3.1.3 Treatment of osteoporosis 
Advances in understanding the pathogenesis of osteoporosis have lead to novel therapies 
that inhibit excessive bone resorption and increase bone formation. Lifestyle modifications 
including cessation of smoking, low alcohol intake, and regular exercise together with 
adequate calcium and vitamin D supplementation form an important baseline treatment of 
osteoporosis. In addition, various medical treatments are available (Rachner et al. 2011) that 
have been shown to decrease the fracture risk for both vertebral and non-vertebral fractures 
(Black et al. 1996; Cummings et al. 1998; Delmas et al. 2002; Reginster et al. 2005; Black et al. 
2007; Greenspan et al. 2007). The drugs can be divided into those that decrease resorption, 
i.e., antiresorptive drugs and those that increase bone formation, i.e., anabolic drugs. 
Although long-term side effects are not completely clear, the new therapies combine better 
efficacy and convenient administration which may achieve better compliance to the therapy 
when compared to the older therapies (Rachner et al. 2011).  
Calcium and vitamin D are a baseline treatment for every patient with osteoporosis. In 
the elderly, vitamin D deficiency has been associated with lower BMD, high turnover, and 
increased risk of falls and hip fractures (Sambrook and Cooper 2006). ASBMR recommends 
adequate dietary calcium uptake rather than calcium supplements or combined calcium 
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and vitamin D supplementation. This is because of the suspected cardiovascular adverse 
effects related to calcium only supplementation (Pentti et al. 2009; Bolland et al. 2010). 
There is a speculation that the increased risk of cardiovascular events might have been due 
to vitamin D deficiency (Holick 2007). The recommended 25-hydroxyvitamin D (25-OHD) 
level is extremely controversial. It has been concluded by the Institute of Medicine (2011) 
that the limit for insufficiency of serum 25-OHD levels is less than 50 nmol/L. To achieve a 
25-OHD level 75 nmol/L, usually the required daily dose of vitamin D is 800 IU (Rachner et 
al. 2011). For adults, the recommended calcium intake is 800 mg daily (NNR 2012a). In a 
Finnish study, calcium and vitamin D supplementation (1000 mg/800IU) tended to reduce 
the fracture risk, however, no statistical significance was achieved (Salovaara et al. 2010). 
Hormone replacement therapy (HRT) has been used in the prevention and treatment of 
osteoporosis in postmenopausal women. A reduced rate of osteoporotic fractures has been 
related to HRT due to its antiresorptive effects (Rossouw et al. 2002; Anderson et al. 2004). 
However, an increased rate of strokes has been associated with both combination therapy 
(estrogen and progestagen) (Rossouw et al. 2002) and estrogen alone therapy (Anderson et 
al. 2004). There has also been an increased rate of cardiovascular events related to the 
combination therapy. An increased risk of breast cancer has been related to combination 
therapy (Rossouw et al. 2002) whereas prolonged estrogen alone therapy has reduced the 
risk of breast cancer (Anderson et al. 2004). Women with osteoporosis and cardiovascular 
risk factors should be treated with an alternative medication for osteoporosis. However, 
symptomatic women with high fracture risk around the menopause can receive HRT but 
only for a short time (Rossouw et al. 2002; Pentti et al. 2006; Sambrook and Cooper 2006). 
Selective estrogen-receptor modulators (SERMs) are diverse compounds that have a 
tertiary structure similar to estrogen to allow them to bind to the estrogen receptor, and 
therefore, they can exert antagonist or agonist effects selectively on various tissues with 
estrogen receptors (Sambrook and Cooper 2006). Raloxifene is the most studied compound 
having less effect than BPs on both bone turnover markers (reduction of 30-40%) and BMD 
(Delmas et al. 1997; Johnell et al. 2002; Sambrook et al. 2004). Raloxifene has reduced the 
vertebral fracture rate by almost 50% in patients with no fracture history (Ettinger et al. 
1999; Delmas et al. 2002) but no effects to achieve a reduction of hip fractures have been 
found (Delmas et al. 2003). Raloxifene can cause vein thrombosis and exacerbate hot flushes 
(Cummings et al. 1999). 
Bisphosphonates (BPs) are widely used as an antiresorptive treatment for osteoporosis. 
They have high affinity on bone and a long half-life, and thus, may remain in bone for 
decades (McClung et al. 2001). In clinical trials, BPs have been shown to reduce the risk of 
both vertebral fractures (40-50%) and non-vertebral fractures (20-40%, including hip 
fractures) (Cranney et al. 2002). BPs can be administered either orally or intravenously. The 
treatment is inexpensive and suitable for several types of osteoporosis such as 
postmenopausal, male, and GC-induced (Rachner et al. 2011). BPs can also be used in 
children (Chapter 2.3.2) (Papapoulos 2011). In postmenopausal women, other 
antiresorptive therapies, i.e., raloxifene, strontium renelate, and denosumab can be used as 
alternative therapies. The present antiresorptive therapies have impressive antifracture 
efficacy but their use is sometimes limited by adverse effects (mainly upper 
gastrointestinal), concomitant comorbidities, or poor long-term compliance (Siris et al. 
2009). Bone turnover markers have been suppressed for as long as five years after 
discontinuation of treatment (Ensrud et al. 2004). A histomorphometric evaluation revealed 
a reduction in the bone forming surfaces by as much as 40-60% with usual BP doses 
(Chavassieux et al. 1997). It has also been postulated that the reduced bone turnover might 
lead to microdamage accumulation over time, and thus, to an impaired fracture repair 
(Sambrook and Cooper 2006). A rare but serious adverse effect, osteonecrosis of the jaw, 
has also been reported in some patients on BP therapy but these cases are mainly restricted 
to patients treated with high BP doses or many BPs for cancer (Marx 2003; Ruggiero et al. 
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2004). There are reports of atypical femoral fractures (AFFs) related to BPs (Shane et al. 
2010; Schilcher et al. 2011; Dell et al. 2012, Meier et al. 2012, Schilcher et al. 2013). 
A new antiresorptive agent, denosumab, has recently been approved in Europe for the 
treatment of osteoporosis and in USA for the treatment of osteoporosis and bone metastases 
(Rachner et al. 2011). Denosumab is a fully human monoclonal antibody against RANKL 
with high specificity and affinity for RANKL. Bone turnover markers decrease during the 
treatment with this agent (Bekker et al. 2004) and increase rapidly after discontinuation of 
the therapy (Miller et al. 2008). According to bone histomorphometry, over 50% of the 
patients given denosumab had no osteoclasts. Additionally, decreased bone formation and 
remodeling have been observed (Reid et al. 2010). The risk of new vertebral fractures was 
reduced by 58% over the period of three years, and similarly, the risk of hip fractures was 
reduced by 40% and other non-vertebral fractures by 20%. Osteonecrosis of the jaw and 
atypical femoral fractures are the greatest concern as a side effect of the treatment 
(Paparodis et al. 2013; Pichardo et al. 2013; Rachner et al. 2013). Denosumab can be 
considered as a first-line treatment or it can be given as an alternative to BPs, especially if 
BPs are not tolerated. Denosumab has certain benefits compared to BPs; it does not bind to 
bone, and thus, it is reversible, and because of the subcutaneous administration route, it 
does not evoke any gastrointestinal side effects. Better adherence to the therapy may be 
achieved by its administration twice a year compared with weekly or monthly treatments 
with BPs. Denosumab is not eliminated by the kidneys and is therefore safer in patients 
with impaired kidney function although dose adjustments may be necessary in those with 
lower creatinine clearance levels (<30 mL/min) (Rachner et al. 2011).  
Bone anabolic drugs stimulate bone formation. The intact PTH (hPTH 1-48) or its N-
terminal fragment (hPTH 1-34) called teriparatide are available at the moment and can be 
administered subcutaneously (Daddona et al. 2011). There is a report that teriparatide (dose 
20 μg daily) can reduce the risk of new vertebral fractures by 65% and it can decrease non-
vertebral fractures by 53%. The beneficial effects on BMD seem to vanish after 
discontinuation of the therapy (Neer et al. 2001). Intact PTH has reduced the rate of new 
vertebral fractures by 68% in patients with no previous fractures (Greenspan et al. 2005). 
The combination therapy with BPs does not seem to be more effective than PTH alone but 
further studies are needed to investigate these combined effects (Black et al. 2005). 
Continuous treatment with PTH leads to bone loss whereas intermittent PTH therapy 
enhances bone formation (Rubin and Bilezikian 2003; Keller and Kneissel 2005; Eriksen 
2010). 
Strontium renelate is a compound that both decreases bone resorption and increases 
bone formation although its exact mechanism of action remains unclear (Meunier et al. 
2004). In postmenopausal women, the risk of clinical vertebral fracture has decreased 52% 
whereas the reduction in the risk of non-vertebral fractures has been lower (16%). Adverse 
effects include venous thrombosis for unknown reasons and gastrointestinal discomfort 
(Reginster et al. 2005). 
There are also other promising targets for novel treatment of osteoporosis including 
cathepsin K, Dickkopf, and sclerostin inhibitor (Sambrook and Cooper 2006). The number 
of new approved bone therapies is expected to increase in the coming years (Rachner et al. 
2011). For example, the novel cathepsin K inhibitor, odanacatib, targets mature osteoclasts 
inhibiting bone resorption while preserving osteoclast viability (Stoch et al. 2009; Bone et al. 
2010). Some promising anabolic drugs also are under development. In the future, calcilytic 
drugs and antagonists of WNT inhibitors might provide an anabolic treatment in 
individuals with severe osteoporosis with excessive bone loss and slow bone healing 
(Rachner et al. 2011).   
 
2.3.1.4 Atypical femoral fractures  
During recent years, it has been proposed that the long-term use of BPs could be related to 
the development of atypical femoral fractures (AFFs) (Shane et al. 2010, Schilcher et al. 
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2011, Dell et al. 2012, Meier et al. 2012, Schilcher et al. 2013). Later, it has been shown that 
long-term BP therapy is not a prerequisite for the development of these fractures (Giusti et 
al. 2010).  BPs have long half-life in bone and they inhibit bone resorption and formation, 
and this could evoke a major suppression of bone turnover (Jamal et al. 2011). There have 
been speculations that prolonged suppression of bone resorption could lead to the 
accumulation of microdamage, and thus, to increased bone fragility (Sellmeyer 2010). 
Patients with AFF may develop a further AFF on the contra-lateral site suggesting that 
there may be a systemic reason that predisposes certain patients to suffer these fractures 
(Giusti et al. 2010). Generally, AFFs are rare and the vast majority of patients on BPs do not 
develop this kind of fractures (Compston 2011, Meier 2012). Surprisingly, the BMD T-score 
was above -2.5 at the time of the fracture in more than 75% of the women with AFF.  
Further, 18% had a normal BMD T-score at that time. This indicates that patients treated 
with BPs without frank osteoporosis (BMD T-score <-2.5) might be at risk of developing 
AFF (Giusti et al. 2010). 
AFFs are characterized by an atypical fracture morphology and occur always as 
insufficiency fractures. The criteria for AFFs have been defined by ASBMR Committee 
(Table 5) (Shane et al. 2010). Further, there are other findings that are commonly present but 
are not essential for the diagnosis. Prodromal pain has been common as well has several 
comorbid conditions and bilaterality of the fractures. Delayed fracture healing has often 
been reported. Cortical thickening has often been found, and the co-administration of some 
other drugs, such as proton-pump inhibitors or GCs, may have a role in the pathogenesis of 
AFFs (Shane et al. 2010). However, it is not known whether the cortical thickening is 
actually caused by BP therapy. There is one report of cortical thickening during alendronate 
treatment (Lenart et al. 2009) whereas another study detected thick cortices before the BP 
treatment (Kwek et al. 2008). Further, BP-naïve patients with AFF have thick cortices (Giusti 
et al. 2011), and another study found no significant differences in the cortical thickness 
before and at 7 years after BP-therapy (Unnanuntana et al. 2012). Thus, the data available 
does not support the theory that BPs would cause cortical thickening (Compston 2011). A 
recent study used different criteria for an AFF and found even higher association with 
bisphosphonate use (Schilcher 2013). The fracture angle from 75° to 125° and presence of 
callus reaction showed high specificity to detect bisphosphonate use.  
 
Table 5. The major criteria of atypical femoral fractures (AFFs) as defined by ASBMR 
Committee. Modified from Shane et al. (2010).  
 
Major features of AFFs 
Fracture at subtrochanteric or diaphyseal region 
Fracture associated with no trauma or minimal trauma, i.e., a fall from maximum a standing 
height 
Transverse or short oblique configuration of the fracture without comminution 
Incomplete fractures may involve only lateral cortex whereas complete fractures occur through 
both cortices 
A medial spike may be associated 
 
Epidemiological studies have revealed that BP-treated women with AFF have lower 
mean age (68 years) compared to those with subtrochanteric or femoral shaft fractures (73-
79 years), and the patients seem to sustain AFFs at any age (Salminen et al. 1997; Salminen 
et al. 2000; Weiss et al. 2009; Nieves et al. 2010). The similar fracture morphology has also 
been identified in patients without a history of BP treatment or without a metabolic bone 
disease (Kumm et al. 1997; Niimi et al. 2008; Lenart et al. 2009; Schilcher and Aspenberg 
2009). It has been postulated that BP treatment could cause increased risk for 
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subtrochanteric fractures whilst decreasing the risk for femoral neck fractures. Thus, a 
secondary analysis of large randomized controlled BP trials (FIT, FLEX, HORIZON) was 
performed (Black et al. 2010) which noted no increase in the incidence of subtrochanteric 
fractures compared to placebo but the X-rays were not available and the duration of the 
treatment was relatively short (Black et al. 2010). In contrast, Abrahamsen et al. suggested 
that there was an increased incidence of subtrochanteric fractures related to BP use but the 
risk was not dose-dependent (Abrahamsen et al. 2010). A similar trend was found by Wang 
and Bhattacharyya (Wang and Bhattacharyya 2011). The risk of AFFs has shown to increase 
with longer duration of the treatment (Schilcher 2011, Dell 2012, Meier 2012). AFFs have 
often been described to be related to the use of alendronate but there are also reports of 
AFFs on other BPs such as risendronate and ibandronate as well as denosumab in the 
literature. The duration of BP use before the AFF has varied from 3 months to 16 years 
(Giusti et al. 2010; Paparodis et al. 2013). 
The pathophysiology of AFFs remains to be established (Giusti et al. 2010; Compston 
2011). The suppression of bone turnover evoked by BPs may have adverse effects on bone 
material properties and strength. The underlying mechanism could be increased 
mineralization, decreased homogeneity of the mineralization, changes in collagen 
composition, and accumulation of microdamage (Compston 2011).  
Only limited histological data is available and most studies have examined iliac crest 
biopsies rather than biopsies at the fracture site (Shane et al. 2010; Compston 2011). Bone 
formation has generally been decreased after BP treatment but some studies have found 
normal or even increased resorption parameters. Giusti et al. performed a review of the 
literature on BP treated patients and concluded that 8 of 27 patients had double labels and 
most of the patients had single labels in the biopsy. Thus, an oversuppression of the bone 
turnover seems to be an unlikely explanation (Giusti et al. 2010). Further, Jamal et al. have 
reported bone histomorphometry findings in a 55-year-old woman who had been receiving 
alendronate therapy for 9 years (Jamal et al. 2011). She suffered an atypical femoral fracture 
and a tetracycline labeled biopsy was taken near to the fracture site. In contrast with the 
previous presumptions of oversuppression of bone remodeling due to the BP treatment, 
this patient had normal lamellar bone structure, no cortical or endocortical adynamic bone 
disease, no evidence of mineralizing defect or osteomalacia, and the mineralization was 
normal. The decreased bone turnover could cause an increased incidence of non-vertebral 
fractures but this has not been reported related to the BP use (Bone et al. 2004; Black et al. 
2006). Thus, the atypical femoral fractures may not be due to the oversuppression of bone 
turnover (Jamal et al. 2011).  
2.3.2 Osteoporosis in children 
Osteoporosis has been recognized as an increasing health problem among children and 
adolescents. This is because there is now a better appreciation of the importance of the bone 
mass laid down at the end of growth as a major determinant of the risk of osteoporosis later 
in life. Further, many even apparently healthy children may sustain repeated fractures 
during their childhood (Bianchi 2007; Mäyränpää et al. 2011). By the age 18, about 90% of 
the peak bone mass will have been acquired (Bailey et al. 1999) and adequate calcium and 
vitamin D uptake and regular exercise play important roles in this process (Bianchi 2007). 
The significance of low BMD and association with fractures is less well-established in 
children than in adults. The diagnostic criteria for osteoporosis in children were first 
established in 2007 by Pediatric Official Positions of the International Society for Clinical 
Densitometry (ISCD). It is clear that early diagnosis of juvenile osteoporosis is important for 
appropriate intervention (Mäyränpää et al. 2011).  
As in adults, osteoporosis in children may be caused by primary or secondary causes 
(Table 6). Primary osteoporosis is relatively rare; multiple fractures are common in children 
with primary osteoporosis. Idiopathic juvenile osteoporosis has been thought to be a self-
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limiting disease characterized by repeated fractures that spontaneously resolve after 
puberty (Bianchi 2007). 
 
Table 6. Primary and secondary causes of osteoporosis in children (Rauch and Glorieux 2004; 
Bianchi 2007). GC = glucocorticoid. 
 
Primary causes of osteoporosis 
Secondary causes of osteoporosis related to 
multiple chronic conditions 
Hereditary disorders of connective tissue e.g. 
osteogenesis imperfecta 
Idiopathic osteoporosis 
Neuromuscular disorders e.g. Duchenne muscular 
dystrophy 
Chronic disorders e.g. cystic fibrosis, 
malabsorption, organ transplantation 
Endocrine disorders e.g. delayed puberty 
Inborn error of metabolism e.g. protein intolerance 
Iatrogenic causes such as GCs and radiotherapy 
 
DXA has been most commonly used to measure bone mass in children as well as in 
adults. The good reproducibility, and precision are advantages of this technique. Since 
three-dimensional bone structure is measured by a two-dimensional approach using DXA, 
the method measures only areal BMD, not volumetric BMD. DXA also fails to distinguish 
between cortical and cancellous bone (Bianchi 2007). Falsely low BMD values might be 
observed in children of short stature or in those with delayed skeletal maturation because 
the reference values are obtained from healthy children (Bachrach and Sills 2011). Thus, it is 
essential to correct the BMD values in children for bone size, body height and/or bone age 
(Kröger et al. 1993; Rauch et al. 2008).  
The diagnosis of osteoporosis in children is challenging. Biochemistry and bone turnover 
markers seem to provide little help in evaluating bone mass and the susceptibility to 
fractures (Mäyränpää et al. 2011). The diagnosis of osteoporosis in pediatric patients should 
include a significant fracture history in addition to a low bone mineral content (BMC) or 
BMD (Rauch et al. 2008). However, a fragility fracture in adults is usually considered as a 
complication of osteoporosis, and therefore, the diagnosis of osteoporosis in children might 
be delayed. For densitometry, BMD values are interpreted in terms of standard deviation 
scores which are compared with ethnicity-, age-, and gender matched healthy controls (Z-
score) (Bianchi 2007) that can be further adjusted for bone size, body height and /or bone 
age (Kröger et al. 1993; Rauch et al. 2008).  Z-score values below -2.0 are considered as a 
serious warning of osteoporosis. A significant fracture history is defined when at least one 
of the following criteria is included: 1) a vertebral compression fracture, 2) one lower 
extremity long bone fracture, or 3) two or more upper extremity long bone fractures (Rauch 
et al. 2008). Because of the difficulties in establishing the diagnosis of osteoporosis in 
children, bone biopsy and histomorphometric analysis may be considered in patients who 
have a high-risk for osteoporosis and other metabolic bone diseases, such as after organ 
transplantation (Helenius et al. 2006; Valta et al. 2008) or in children with repeated fractures 
(Mäyränpää et al. 2011). Nonetheless, the diagnosis of osteoporosis in children needs to be 
definite before starting bone medications, e.g., with BPs since these drugs may have 
adverse effects on mineral homeostasis and renal function.  
In order to achieve optimal bone growth, sufficient dietary calcium intake is 
recommended for all children but it has been claimed that only 25% of boys and 10% of 
girls aged 9-17 years meet the recommendations (National Institutes of Health Consensus 
2001). The children with diagnosed osteoporosis should be evaluated for adequate calcium 
and vitamin D levels and supplementation started when appropriate (Bianchi 2007). In 
Finland, a national recommendation for vitamin D supplementation in children has been 
given due to the northern location of the country: 10 μg (400 IU) in under 2-year-old 
children and 7.5 μg (300 IU) for children aged 2 to 18 years (NNR 2012b). Before starting 
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any bone specific drugs, the cause of osteoporosis should be identified and risk factors for 
the disease reduced or eliminated (Bianchi 2007). BPs have been shown to increase BMD, 
reduce the rate of fragility fractures, and relieve pain together with providing increased 
mobility in children with secondary osteoporosis (Glorieux et al. 1998; Bianchi et al. 2000; 
Shaw and Bishop 2005). They are the only antiresorptives that have been successfully used 
in pediatric patients (Bianchi 2007). Cyclical intravenous pamidronate or oral alendronate 
have been the most commonly provided treatments (Glorieux et al. 1998; Bianchi et al. 2000; 
Shaw and Bishop 2005).  
2.3.3 Renal osteodystrophy 
Renal osteodystrophy is the term used to describe the skeletal complications of end-stage 
renal disease, i.e., disturbances in bone metabolism and remodeling (Hruska and 
Teitelbaum 1995). Chronic kidney disease (CKD) is characterized by progressive loss of 
kidney function (Eknoyan et al. 2004), and there is increasing evidence indicating that CKD 
is associated with cardiovascular complications including vascular calcification, morbidity, 
and mortality (Block and Cunningham 2006). Renal failure leads to changes in mineral 
(calcium, phosphorus) and hormonal metabolism (PTH, vitamin D). These disturbances 
further cause skeletal abnormalities such as changes in bone structure, bone turnover, and 
cellular level. An increased bone fragility and fractures have been associated with renal 
osteodystrophy (Moe and Drueke 2004). Biochemical markers may provide information 
about the underlying bone disease but the definite diagnosis and classification of renal 
osteodystrophy is based on bone histomorphometric analysis. Plasma levels of PTH 
together with serum levels of calcium, phosphorus, and ALP, however, have been used to 
evaluate bone turnover, to diagnose, and to monitor the success of the treatment of renal 
osteodystrophy. According to the latest recommendations by a foundation called Kidney 
Disease: Improving Global Outcomes (KDIGO), renal osteodystrophy should be 
distinguished from chronic kidney disease – mineral and bone disorder (CKD-MBD) (Moe 
et al. 2006). CKD-MBD is defined as a systemic disorder of mineral and bone metabolism 
caused by CKD, and its manifestations may include biochemical, vascular, or skeletal 
abnormalities. Renal osteodystrophy, however, is one component of CKD-MBD accounting 
for altered bone morphology that is quantifiable by bone histomorphometry (Moe et al. 
2006).    
2.3.4 Solid organ transplantation and related bone complications in children 
Solid organ transplantation is an established treatment for children with end-stage renal 
disease, acute or chronic liver failure, terminal lung or intestinal disease, and with dilated 
cardiomyopathy as well as other terminal heart diseases. While the overall long-term 
patient survival has improved, new health concerns have emerged, i.e., secondary 
osteoporosis and fragility fractures (Cohen and Shane 2003; Cohen et al. 2004). Metabolic 
abnormalities related to the underlying disease, life-long immunosuppressive medication, 
especially GCs, and disturbances in pubertal development, may affect normal bone 
metabolism and lead to low bone mass and an increased fracture risk in pediatric 
transplant patients (Hill et al. 1995; Acott et al. 2003; Helenius et al. 2006; Valta et al. 2008; 
Valta et al. 2009; Sachdeva et al. 2010). Furthermore, impaired kidney function and a 
subsequent metabolic bone disease may occur also in pediatric liver and heart transplant 
recipients due to the nephrotoxicity of calcineurin inhibitors (Bharat et al. 2009; Kivela et al. 
2011).  
A greatly increased fracture risk has been observed in pediatric patients after solid organ 
transplantation (Hill et al. 1995; Helenius et al. 2006; Valta et al. 2008; Valta et al. 2009). 
High doses of GCs are frequently needed immediately after transplantation and during 
rejection periods. The GC-related fracture rate has been at its highest during 3-12 months 
after transplantation (Ebeling 2009). Even small doses of GCs increase fracture risk 
significantly (Van Staa et al. 2000). In a Finnish population-based study, the incidence of all 
fractures was 6-fold higher in children after solid organ transplantation compared to 
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controls in a 5-year follow-up time. Further, the incidence of vertebral fractures was 160-
fold higher in the study cohort compared to that in the control group. Approximately 50% 
of vertebral fractures were asymptomatic, and thus, a systematic screening of vertebral 
fractures at regular intervals has been recommended. Male sex, pre-transplant fractures, 
older age, and liver transplantation were found to be risk factors for post-transplantation 
fractures (Helenius et al. 2006).   
Only one study has evaluated skeletal findings by bone histomorphometry in children 
after solid organ transplantation. Sanchez et al. (1998) performed bone biopsies on 47 
pediatric renal transplant patients at 3.2 ± 1.7 months after transplantation. Thirty-one 
(66%) of the 47 patients had normal bone formation in histomorphometry, while 23% had 
high-turnover renal osteodystrophy, and 8% displayed adynamic bone lesions. In these 
subgroups, no difference was found between the time from transplantation, cumulative GC 
dose, or the time on dialysis. The serum PTH values did not differ between the patients 
with normal bone formation, high turnover or adynamic bone. Defective skeletal 
mineralization with increased osteoid volumes and decreased mineral apposition rates was 
found in a substantial proportion of the patients. In addition, this study revealed that after 
adjusting the DXA values for height and age, low bone mass and osteoporosis were not 
common in pediatric patients shortly after transplantation (Sanchez et al. 1998). In adults, 
increased bone resorption biochemical markers and decreased bone formation biochemical 
markers have been detected shortly after transplantation whereas with the reduction in the 
GC doses in the later post-transplantation time, bone formation begins to increase (Shane 
and Epstein 2001). Bone formation parameters, as measured by histomorphometry, have 
been shown to increase significantly in adult patients at 3 months after liver transplantation 
(Vedi et al. 1999).  
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3  Aims of the Study 
This study aimed to resolve the role of qualitative properties of bone beyond bone density 
measurements. Changes in biological aspects of bone quality were characterized by 
quantifying bone remodeling using bone histomorphometry in specific cohorts of adult and 
pediatric patients. This was combined with studies of the bone microarchitecture and 
composition using micro-computed tomography and Fourier transform infrared 
spectroscopic imaging.   
 
The specific aims of the study were: 
 
1. To characterize bone properties using bone histomorphometry and micro-CT to 
resolve whether the agreement of histomorphometry and micro-CT would depend 
on the metabolic status of bone. A further objective was to determine whether micro-
CT is able to detect the differences between diseased and healthy bone. 
2. To resolve the incidence of atypical femoral fractures in Kuopio University Hospital 
district, Kuopio, Finland, and to add these histomorphometric findings of patients 
with atypical femoral fractures to the growing international database. Further aims 
were to characterize bone composition in these patients with atypical fractures.  
3. To determine whether bone composition would differ between the fracture-prone 
children with and without vertebral fractures.   
4. To characterize bone histomorphometric findings in pediatric kidney, liver, and 
heart transplant recipients who were being evaluated for suspected post-
transplantation osteoporosis. 
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4  Materials and Methods 
4.1 PATIENTS AND STUDY DESIGN 
4.1.1 Patients (I-IV) 
Study I comprised 36 patients (46.0 s 18.5 years, 16 males) with iliac crest biopsies to study 
the reproducibility and agreement between micro-CT and bone histomorphometry. Iliac 
crest biopsies (n=36) were collected including either both cortices (n=15) or only one cortex 
(n=21). The patients were selected based on histomorphometric evaluation and diagnosis. 
The patients with osteoporosis had a history of fractures, kidney disease, familial 
osteoporosis, or organ transplantation. The patients with renal osteodystrophy had a 
history of diabetes, dialysis, nephrosis, kidney transplantation, fractures, or 
glomerulonephritis. Based on the histomorphometric diagnosis, 15 of the patients had 
osteoporosis, 11 had renal osteodystrophy, and 10 had normal bone biopsy findings. Some 
of the normal samples (n=6) were obtained from cadavers with no medical history known 
to have any effect on bone metabolism.  
In Study II, all femoral fractures with the diagnosis code S72.2, S72.3, or S72.4 (ICD-10 
clinical coding system), or patients aged >49 years with fractures treated with a femoral 
intramedullary nail (NOMESCO procedural code NFJ60), were identified from Kuopio 
University Hospital Patient Discharge Registry. Kuopio University Hospital is responsible 
for the care of all surgically treated trauma patients in its catchment area of 248 000 
inhabitants in Eastern Finland. The reviewed time period extended from January 2007 to 
December 2009. All preoperative radiographs were reviewed to identify femoral diaphyseal 
fractures, defined as fractures in the region of the femur between 5 cm distal to the lesser 
trochanter and the junction of the middle and distal third of the femur. These patients who 
met the major criteria for AFF defined by ASBMR were identified (Shane et al. 2010), 
including one patient who had fallen from a 0.5 m high stack of wood. The assessment of 
radiographs was conducted blind to the patients’ medication. Pathological fractures caused 
by underlying malignancy were excluded. Further, the records of the patients that 
underwent bone histomorphometric evaluation at the Kuopio University Hospital, Kuopio, 
Finland due to an AFF were identified (n=7). Three of these samples had to be excluded 
from the report (1 malignancy, 1 cortical bone sample, 1 with long time, i.e., 3.8 years from 
AFF to biopsy). Thus, the findings from the remaining patients (n=4) are reported.  
The prevalence data on continuous treatment with BP medication (ATC codes M05BA: 
BPs and M05BB: BPs, combinations) in the catchment area of Kuopio University Hospital 
was provided by the Finnish Social Insurance Institution’s prescription database (Study II) 
(Furu et al. 2010). Statistics Finland provided the population data for the area of interest. All 
clinical data were acquired from medical records with information on comorbidities, 
duration of BP treatment, surgical treatment of fracture, and outcome. All patients were 
contacted via telephone to verify the data. The daily dose of alendronate was 10 mg until 
2008 when it was changed to a weekly dose of 70 mg. The monthly dose of ibandronate was 
150 mg. BP treatment was discontinued at the time that the diagnosis of the AFF was made.  
In Study III, children with suspected primary osteoporosis where evaluated to 
characterize underlying bone changes by FTIRI together with clinical characteristics. Iliac 
crest biopsies were obtained from 24 children (aged 6.7-16.6 years, 17 males) with suspected 
primary osteoporosis. Primary osteoporosis was suspected based on either (i) low BMD [an 
SD score (Z-score) ≤ -2.0], or (ii) history of increased fragility, i.e., several non-vertebral 
fractures and/or low-energy vertebral fracture(s), and (iii) exclusion of secondary causes of 
osteoporosis. All children had sustained fractures and there was no significant difference in 
children that had sustained peripheral fractures between the children with (n=14) and 
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without (n=10) vertebral fracture. However, the average number of peripheral fractures was 
4.1 ± 1.1 for children without vertebral fractures and 1.9 ± 1.8 for children with additional 
history of vertebral fracture (Mäyränpää et al. 2011). Children who had sustained high-
energy fractures, comparable to a fall from ≥ 3 meters, were not included in the study.  
In Study IV, bone changes were characterized by bone histomorphometry as a part of 
clinical evaluation for suspected osteoporosis in pediatric patients after solid organ 
transplantation. Iliac crest bone biopsies were taken from 19 children and adolescents with 
a history of kidney (n=6), liver (n=9), or heart (n=4) transplantation (age range 7.6-18.8 years, 
11 males). The suspicion of secondary osteoporosis was based on low areal BMD (aBMD) 
measured by DXA and/or fracture history. All children had received GCs since 
transplantation and were receiving low-dose alternate-day oral GCs (methylprednisolone). 
Total cumulative (mg) and weight-adjusted (mg/kg) GC doses as well as GC exposure 
(mg/kg/days) during previous three years were calculated as methylprednisolone 
equivalents for each patient. None of the children had been treated with aluminum-
containing phosphate binders or BPs. All patients were clinically assessed by a pediatric 
nephrologist.  
 
Table 7. Main characteristics for studies I-IV. 
 
Study Number of subjects (n) Males/ Females (n) Age mean ± SD (years) 
I 36 16/20 46 ± 19 
II 8 1/7 71.2 ± 11.8 
III 24 17/7 12.0 ± 2.6 
IV 19 11/8 15.3 ± 2.9 
 
The patient characteristics are summarized in Table 7. The study protocol was approved 
by the local healthcare authorities and the local ethics committee (Research Ethics Board, 
Kuopio University Hospital, Kuopio, Finland in Studies I and II; and Ethics Committee, 
Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland in Studies III 
and IV). 
4.1.2 Growth and pubertal assessment (III, IV) 
Height was reported as standard deviation (SD) units (Z-score) based on Finnish reference 
data. BMI was calculated as weight in kilograms divided by square of height in meters 
(kg/m²) and transformed into Z-scores using age- and gender-specific reference data 
provided by WHO (WHO 2006). Pubertal maturation was recorded according to Tanner 
(Tanner 1962). 
4.1.3 Radiology and biochemistry (II, III, IV) 
Radiographs at the fracture site were available for all patients in Study II. The fractures 
were classified according to the major criteria defined by ASBMR (Shane et al. 2010) by two 
orthopedic surgeons.   
In Study III, thoracic and lumbar radiographs were available for all children (standard 
anterior-posterior and lateral neutral radiographs in supine position). In Study IV, bone 
age was determined from a plain radiograph of the left hand according to Greulich and 
Pyle (Greulich and Pyle 1959). In Study III, the diagnosis of vertebral fracture was 
established by two observers, who worked independently and then reviewed the results to 
reach a consensus (digitized images, AGFA ImPacs System®). In Studies III and IV, the 
classification of vertebral changes was based on previous work by Mäkitie et al. (2005). A 
reduction of ≥ 20% in anterior, middle, or posterior vertebral height was considered 
significant (Mäkitie et al. 2005). 
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Bone densitometry (Lunar Prodigy device, General Electric Medical Systems, Lunar, 
Liegen, Belgium) had been previously performed for some of the patients in Study II. 
Based on BMD values, T-score values were calculated. In Studies III and IV, areal BMD for 
the lumbar spine (L1-L4) and total hip (Study IV) were measured within six months of the 
biopsy by DXA (Hologic Discovery A®, Bedford, USA) using pediatric software (version 
12.4). Values were transformed into BMD Z-scores by using age- and sex-specific reference 
data; these reference values have been shown to be appropriate for Finnish children (Valta 
et al. 2009). In children with compressed vertebrae in the plain radiographs of the lumbar 
spine, the BMD result was re-analyzed excluding the affected vertebrae. The Z-scores were 
corrected for bone age, provided that skeletal maturity was delayed or advanced by more 
than one year.  
In Studies III and IV, blood and urine samples were collected from all children before 
noon (fasting blood tests in Study IV). By using standard methods, plasma concentrations 
of ionized calcium (P-Ca-ion), phosphate (P-Pi), and creatinine (P-Crea) were determined. 
For alkaline phosphatase (P-ALP), age- and sex-dependent reference values were used 
(Saarinen et al. 2010). Glomerular filtration rate (GFR) was measured by 51-labeled 
chromium ethylenediaminetetraacetic acid clearance (Study IV). Kidney function was 
classified as normal (GFR > 90 ml/min/1.73 m2; CKD stage 1), mild kidney dysfunction (GFR 
60 - 89 ml/min/1.73m2; CKD stage 2), and moderate kidney failure (GFR 30 - 59 
ml/min/1.73m2; CKD stage 3). Urine samples were analyzed for calcium and creatinine ratio 
(U-Ca/U-Crea ratio, normal reference value ≤ 0.7 mmol/mmol) (Study IV). Serum 
concentration of 25-hydroxyvitamin D (S-25-OHD) was determined by high performance 
liquid chromatography followed by UV detection (HP® 1100 Liquid Chromatograph). 
Hypovitaminosis D was defined as S-25-OHD below 50 nmol/L and vitamin D deficiency 
below 37.5 nmol/L (Misra et al. 2008). Plasma parathyroid hormone (P-PTH) was measured 
by a solid-phase enzyme-labeled chemiluminescent immunometric assay (IMMULITE® 
2000, DPD, Diagnostic Products Corporation, Los Angeles, CA); the reference range was 8-
73 ng/L. In Study III, the bone formation marker N-terminal propeptide of type I 
procollagen (P1NP) and the bone resorption marker C-terminal telopeptide of type I 
collagen (1CTP) were determined as previously described (Saarinen et al. 2010; Mäyränpää 
et al. 2011). 
4.2 ASSESSMENT OF BONE QUALITY 
Table 8. Methods used in each study to quantify bone quality. 
 
Study Methods used to evaluate bone quality 
I Bone histomorphometry 
Microcomputed tomography 
II Bone histomorphometry 
Fourier transform infrared spectroscopic imaging  
III Bone histomorphometry 
Fourier transform infrared spectroscopic imaging  
IV Bone histomorphometry 
4.2.1 Bone biopsy and histomorphometry (I-IV) 
Iliac crest bone samples were obtained from a standardized site located at 2 cm below and 
posterior to the anterior superior iliac spine. In Studies I and II, the biopsies were obtained 
with a Bordier bone biopsy trephine (Rochester Bone Biopsy®, Medical Innovations 
Incorporation Inc., USA). In Studies III and IV, the biopsies were taken with a 5 mm bone 
biopsy trephine (modified Bordier) (Study III) and/or a 7.5 mm bone biopsy trephine 
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(Rochester Bone Biopsy®, Medical Innovations Incorporation Inc., USA) (Studies III and IV). 
Fluorochrome double labeling was performed prior to biopsy in most cases; in Study I in 25 
of the 36 patients, in Study IV in 18 of the 19 children, or for all patients in Studies II and 
III. Tetracycline was used as a fluorescent agent in two separate 2-day courses, at a dose of 
1500 mg per day in adults (Studies I and II) and 15-20 mg/kg/day (maximum of 1000 
mg/day) in children (Studies III and IV). The interval between the two tetracycline courses 
was 10 days and the medication was terminated four days before the biopsy. The biopsy 
samples were fixed in 70% ethanol for at least 48 hours before embedding in polymethyl 
metacrylate (PMMA). In Study III, the iliac crest biopsies were taken mainly within 12 
months of the fractures (n=19), but in some cases up to 18 months had elapsed since the 
fracture (n=5). In Study IV, the median time interval from organ transplantation to the bone 
biopsy was 4.6 years (range 0.6-16.3 years). 
Bone histomorphometry (Bioquant OsteoII, Bioquant Image Analysis Corporation, 
Nashville, TN, USA) was performed for all samples. In Study I, the analysis was repeated 
two times on different days. In the light microscopic evaluation, 3 μm (Studies I, III, and IV) 
or 5 μm (Study II) thick sections were cut with a microtome and stained with modified 
Masson Goldner trichrome stain. Unstained sections (thickness 7 μm in Studies I, III, and IV 
and thickness 5 μm in Study II) were used for polarized light and fluorescence microscopy. 
For each sample, one (Studies I, II, and IV) or two (Study II) sections were randomly 
selected and analyzed with bone histomorphometry. Regions of interest (ROI) were 
carefully selected to ensure that only cancellous bone was measured, i.e., no cortical or 
subcortical bone was included. The tissue area varied depending on the sample size. The 
magnification used in all measurements was 200x. The nomenclature, abbreviations, and 
units adhered to the recommendations by ASBMR (Parfitt et al. 1987; Dempster et al. 2013). 
In Study II, the mean values of two observers for each parameter are reported except for 
tissue value that is presented as a sum.   
Tissue volume (TV, mm2) was determined by using the whole field of view including 
both trabeculae and bone marrow. Bone volume (BV, mm2) includes both mineralized and 
unmineralized bone volumes. Bone surface parameters (BS/TV, mm-1; BS/BV, mm-1) were 
measured (Study I). Osteoid surfaces (OS/BS, %) were recognized as unmineralized seams 
on the bone surfaces, osteoid thickness (O.Th, μm) was measured, and osteoid volume 
(OV/BV, %) was calculated. The mineralized bone volume was defined (Md.V/TV, %) 
(Study I). Bone cells, osteoblasts and osteoclasts, were determined as a fraction of bone 
surface (Ob.S/BS, %; Oc.S/BS, %). Trabecular thickness (Tb.Th, μm), trabecular number 
(Tb.N, mm-1), and trabecular separation (Tb.Sp, μm) were calculated. Wall thickness (W.Th, 
μm) was measured under polarized light. Dynamic indices were defined in tetracycline-
labeled biopsies using fluorescence microscopy. Mineralizing surfaces (MS/BS, %) were 
measured and the mineral apposition rate (MAR, μm/day) was defined as the interlabel 
width on double labels divided by the number of days between fluorochrome labeling. 
Additionally, activation frequency (Ac.F), bone formation rate (BFR/BS), and osteoid 
maturation time (Omt) are reported in Study IV. Because of scarce labeling in ROI in some 
samples in Studies II and IV, a total of four unstained sections (300 μm apart) were 
analyzed for those samples under fluorescence microscopy in order to evaluate 
fluorochrome labeling (extended label search). 
 
Histological classification based on bone histomorphometry (I, II, IV) 
On the basis of histomorphometric findings in combination with the patient’s history in 
Study I, the samples were grouped into three subgroups: healthy subjects (n=10), patients 
with diagnosed osteoporosis (OP, n=15) and patients suffering from chronic kidney disease 
(renal osteodystrophy, ROD, n=11). The osteoporotic samples were from patients with low 
or high turnover. The renal osteodystrophy samples came from patients with 
hyperparathyroid disease, i.e., high turnover including hyperosteoidosis and increased 
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resorption. Reference values for postmenopausal women were obtained from Recker et al. 
(1988) (mean ± standard deviation) and used for comparisons (Study II). 
In Studies III and IV, the histomorphometric parameters were transformed into SD 
units by comparing them with the reference values to allow cross-sectional comparison of 
the findings. The pediatric age-specific data for transiliac bone histomorphometry was used 
as reference for all parameters (Glorieux et al. 2000) except for the assessment of eroded 
surface (ES/BS), which was determined with a method more commonly used in adults; 
values over 10% were considered as abnormal (Recker et al. 1988; Rehman et al. 1994). After 
quantitative analysis of histomorphometric parameters, the patients were divided into 
subgroups by two experienced readers.  Based on the interpretation of cancellous bone 
volume for age, the samples were divided into low or normal cancellous bone volume 
groups. Low cancellous bone volume was defined as cancellous bone volume (BV/TV) Z-
score below -1.0 and normal bone volume as BV/TV Z-score Ӌ-1.0 as compared with age-
specific normal values (Glorieux et al. 2000).  
Further, the samples were grouped based on the bone turnover rate (low, normal, or 
high turnover for age) in Studies III (Table 9) and IV.  The turnover rates were estimated 
based on Z-score values of formation (osteoid surface [OS/BS], osteoid volume [OV/BV], 
osteoid thickness [O.Th], and osteoblast surface [Ob.S/BS]) and resorption (erosion surface 
[ES/BS] and osteoclast surface [Oc.S/BS]) parameters, as previously described (Mäyränpää 
et al. 2011). It should be noted that in most of the cases the observed changes were more 
than ± 1.0 SD. In Study IV, children with high and low turnover rate were identified; those 
with low turnover rate were re-evaluated in order to detect adynamic bone disease (ABD) 
(Figure 8). ABD was defined according to the previously described criteria, i.e., absence of 
remodeling activity (absence of tetracycline labeling in extended label search), dramatically 
decreased bone formation with either relatively increased or decreased bone resorption, 
and paucity or absence of osteoblasts (Hruska and Teitelbaum 1995; Malluche and Monier-
Faugere 2006; Recker et al. 2011). Mineralization was evaluated and defined as 
osteomalacia if there was clear evidence of suppressed bone mineralization, i.e., no double 
labels in the extended label search (Parfitt 2005; Recker et al. 2011). 
 
Table 9. Turnover rate classification based on bone histomorphometry in Study III.   
Turnover rate Classification criteria 
High turnover (i) both resorption parameters were elevated (ES/BS > 10%, Oc.S/BS > +1.0 SD) 
and/or  
(ii) both formation parameters were elevated (> +1.0 SD) or  
(iii) at least one formation and one resorption parameter were elevated 
Low turnover  (i) both of the formation parameters were low (< -1.0 SD) or  
(ii) mineral apposition rate (MAR) was not measurable 
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Figure 8. Histological bone turnover rate classification in Study IV. The turnover rates were 
classified based on Z-score values of formation (osteoid surface [OS/BS], osteoid volume 
[OV/BV], osteoid thickness [O.Th], and osteoblast surface [Ob.S/BS]) and resorption (erosion 
surface [ES/BS] and osteoclast surface [Oc.S/BS]) parameters. Mineralizing defects or 
osteomalacia were classified as described by Parfitt et al. for adults (Parfitt 2005) but modified 
for children so that ± 2.0 SDs were used as cut-off limits. For osteoid thickness, a different cut-
off limit (+3.0 SD) was used because of the criteria used in adult population (osteomalacic O.Th 
>15 μm which is +2.7 SD) (Recker et al. 1988; Parfitt 2005).  
4.2.2 Microcomputed tomography (micro-CT) (I) 
PMMA-embedded bone cores were imaged twice on different days with a high-resolution 
micro-CT scanner (Skyscan 1172, Aartselaar, Belgium). The samples were scanned by the 
same operator with an isotropic voxel size of 14 μm after the histomorphometry section had 
been obtained. The X-ray tube voltage was 100 kV, current 100 μA, and the scanning time 
for each specimen was between 50 and 75 minutes. The rotation step was 0.40-0.56 degrees 
between each image acquisition, and the frame averaging was 5. A 0.5-mm aluminum filter 
was used for all measurements, and reconstruction of the 2D-cross-sections was performed 
with a modified Feldkamp cone-beam algorithm (NRecon, version 1.5.1.4, Skyscan, 
Aartselaar, Belgium). Volumes of interest (VOI) were carefully selected to exclude the 
cortical and subcortical bone area. An adaptive threshold was used to distinguish bone area 
from non-bone area, and this was kept constant for all samples (Waarsing et al. 2004). The 
adaptive threshold algorithm included a low pre-threshold (global threshold) value to 
binarise thin objects but not noise. After the pre-thresholding, despeckle (three-
dimensional, 3D) was run twice; first to remove white speckles of <20 voxels, and then to 
remove artificial pores inside the bone. The adaptive threshold of the mean of minimum 
and maximum was selected for cancellous bone, using standard analysis methods in CTAn 
software (Skyscan, Aartselaar, Belgium).  
The calculation of the three-dimensional bone parameters and structural indices 
followed the recommendations of American Society of Bone and Mineral Metabolism 
(Parfitt et al. 1987). Bone volume fraction was measured as the percentage of bone volume 
per tissue volume (BV/TV, %), and bone surface per tissue and bone volume were defined 
as bone surface density (BS/TV, μm-1; BS/BV, μm-1). Trabecular thickness (Tb.Th, μm), 
trabecular number (Tb.N, μm-1), and trabecular separation (Tb.Sp, μm) were also 
 
 
 
37 
quantified.  The trabecular pattern factor (Tp.Pf, μm-1) was calculated to describe bone 
connectedness. The structural model index (SMI) was quantified to provide information 
about the predominant shape of the trabeculae in the bone tissue, where values of zero and 
three corresponded to ideal plate and rod structures. The 3D-structural parameters were 
calculated with the CT Analyzer (version 1.6.1.1, Skyscan, Aartselaar, Belgium). 
4.2.3 Fourier transform infrared spectroscopic imaging (FTIRI) (II, III) 
In the FTIRI analysis, 3 μm sections were cut with a microtome (Polycut S®, Reichert-Jung, 
Germany). To ensure that there was no systematic error in section thickness, samples from 
all groups were randomly sectioned in the same session for each study. The samples were 
placed on ZnSe windows, and measurements were conducted with a PerkinElmer 
instrument in the transmission mode (Perkin Elmer Spotlight 300®, Waltham, MA, USA).  A 
spatial resolution of 6.25 μm, a spectral resolution of 4 cm-1, and 8 repeated scans were used 
for data collection. The absorption spectra were recorded between 2000-800 cm-1 
wavenumbers. The background was corrected by measuring the spectrum from a clean site 
of the window with the same measurement parameters, but using 75 repeated scans. Based 
on the bright light microscope image, three to five trabeculae per sample were selected and 
imaged. The differences in section thickness were normalized using the absorbance of the 
PMMA (1728 cm-1) on both sides of the trabeculae (Rieppo et al. 2004). The PMMA 
spectrum was subtracted from every bone spectrum to account for the differences in 
PMMA penetration into the trabeculae (Boskey and Mendelsohn 2005). The bone spectra 
were first normalized to the PMMA peak (1728 cm-1), and subsequently the PMMA 
spectrum was subtracted from the bone spectra (Rieppo et al. 2004; Isaksson et al. 2010). 
The bone spectra were scaled using the same scaling factor back to the original absorbance 
values (Rieppo et al. 2004; Isaksson et al. 2010) (Studies II and III).  
In Study II, age- and sex matched normal samples (n=4, aged 42-75 years, all females), 
which were part of the previous study, were selected for comparison (Isaksson et al. 2010) 
together with two additional samples (n=2, aged 51-58 years, both females). A total of six 
samples were used for comparisons (n=6, aged 42-75 years, mean age 59.0 years). The 
additional samples were obtained from cadavers with no history of metabolic bone disease. 
The cadavers were autopsied within seven days after death. The exclusion criteria included 
severe liver disease, kidney disease, diabetes, rheumatoid arthritis, Crohn disease, 
ulcerative colitis, stomach removal, hyper- or hypothyroid disease, myeloma, malignancy, 
alcoholism, hip prosthesis or similar, previous hormone replacement therapy, or clear 
pathological finding at the sample site. Only ethanol was used in the storage of the 
samples. Measurements were performed as above, with the exception that in the previous 
study four repeated scans were used.  
Constant baseline correction was made for every IR spectrum (custom code, Matlab, 
version 7.6 Mathworks, Natick, MA, USA). The bone mineral content was assessed based 
on the peak areas of phosphate (900-1200 cm-1) and carbonate (850-890 cm-1) peaks (Boskey 
2003). The collagen content was assessed based on the amide I peak area (1585-1720 cm-1) 
(Boskey and Mendelsohn 2005). Collagen cross-linking ratio, i.e., collagen maturity, was 
determined as the ratio between the intensities at 1660 cm-1 and 1690 cm-1 (Donnelly et al. 
2012). A linear baseline correction was performed for each peak before the analyses. The 
bone composition parameters were calculated using previously published methods (Table 
10). In Study III, crystallinity was defined, using peak fitting of the second derivative 
spectrum, as a ratio between the sub-peaks at 1030 cm-1 and 1020 cm-1 (Pleshko et al. 1991). 
It has been shown to correlate with the mineral crystal size and perfection as determined by 
X-ray diffraction (Gadaleta et al. 1996). In Studies II and III, the spatial heterogeneity of 
each compositional parameter was assessed within each sample. The values for each pixel 
were calculated and used to create a histogram using Matlab® (version 7.6 Mathworks Inc.). 
Thereafter, a Gaussian curve was fitted to the histogram, and the full-width-at-half-
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maximum (FWHM) of the Gaussian curve was determined as a measure of heterogeneity 
(Boskey et al. 2009; Turunen et al. 2012). 
 
Table 10. Variables in bone composition based on Fourier transform infrared spectroscopic 
imaging (FTIRI).  
Parameter Measure of 
Phosphate-to amide I ratio Estimates the degree of mineralization, and has been shown to correlate with the ash 
content of the bone (Boskey and Mendelsohn 2005; Boskey and Pleshko Camacho 
2007). 
Carbonate-to-phosphate ratio  Has been suggested to reflect the level of carbonate substitution into the 
hydroxyapatite crystal (Huang et al. 2002; Isaksson et al. 2010). 
Carbonate-to-amide I ratio  Reflects the carbonate content in bone. Carbonate accumulates slowly with age, and 
therefore, high turnover could lead to low carbonate-to-amide I and carbonate-to-
phosphate ratios (Isaksson et al. 2010). 
Collagen cross-linking ratio, 
i.e., collagen maturity 
Has been suggested to reflect the degree of mature to immature collagen cross-links 
(Paschalis et al. 2001).  
Crystallinity Correlates with the mineral crystal size and perfection (Gadaleta et al. 1996). 
4.3 STATISTICAL ANALYSIS (I, III, IV) 
In Study I, the samples were analyzed both after pooling all samples as well as in groups 
based on the metabolic status of the bone. The nonparametric Mann-Whitney U-test was 
used to test differences for each parameter between the study groups. The nonparametric 
Wilcoxon signed rank test was used to confirm that there were no statistical differences 
between the two repeated measurements for each technique. The reproducibility between 
the two repeated measurements for both methods and each parameter was determined 
using the coefficient of variation (CV, %) as described by Glüer et al. (Glüer et al. 1995), as 
well as by calculation of Spearman’s correlation coefficient (ρ). Statistical differences in the 
coefficient of variation between the study groups were analyzed using the Kruskal-Wallis 
test and Mann-Whitney U-test. The agreement between the histomorphometry and micro-
CT measurements was analyzed by Spearman’s correlation analysis using mean values of 
two measurements for both techniques.  
In Study III, the age-specific reference values were used to calculate the bone 
histomorphometric data as SD units (Glorieux et al. 2000). Median values were calculated 
for parameters. The nonparametric Mann-Whitney U-test was used to test differences 
between two study groups for all compositional parameters. The differences between 
children with and without vertebral fractures were tested using Mann-Whitney U-test, as 
well as the differences between the normal and low cancellous bone volume samples. 
Additionally, differences between the turnover rates were defined. Spearman’s correlation 
coefficients were calculated between biochemical and compositional bone parameters. Chi 
Square test was used to test differences when appropriate.  
In Study IV, the bone histomorphometric data were calculated as SD units using the age-
specific reference values (Glorieux et al. 2000). Median values were calculated for 
biochemical markers and bone densitometry; Spearman’s correlation coefficients were 
calculated for various parameters. Samples were analyzed in subgroups based on 
transplantation history, i.e., kidney, liver, or heart transplant. For bone histomorphometric 
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parameters, the nonparametric Kruskal Wallis test was used to test differences between 
more than two subgroups of the samples, and Mann-Whitney U-test was used to test 
differences between two subgroups of the samples. Chi Square test was used to test 
differences when appropriate. Bonferroni correction was used when comparing several 
sample groups. 
Statistical analyses were performed with the SPSS® Statistics software (version 19.0.0, 
SPSS Inc., Chicago, IL). A p-value below 0.05 was considered statistically significant. 
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5  Results 
5.1 REPRODUCIBILITY AND AGREEMENT OF MICRO-CT AND 
HISTOMORPHOMETRY (I) 
5.1.1 Histomorphometry and micro-CT parameters  
Significant differences between the normal, osteoporotic (OP), and renal osteodystrophy 
(ROD) bone samples were found in some micro-CT parameters. When the values obtained 
with both techniques were assessed, OP samples had lower bone volume fraction (BV/TV) 
than normal and ROD samples (p<0.05) (Figure 9, Table 11)). In the micro-CT evalution, 
bone surface (BS/TV) was higher (p<0.05) in ROD samples than in OP samples. Micro-CT 
revealed that normal samples had the highest trabecular thickness (Tb.Th) (p<0.05), and 
trabecular number (Tb.N) was lower (p<0.05) in the OP group than in the normal and ROD 
groups. In OP samples, the trabecular pattern factor (Tb.Pf) was higher (p<0.05) than in 
normal and ROD samples and structure model index (SMI) was higher than in ROD 
samples. 
Figure 9. Bone volume (BV/TV) was lower in osteoporotic patients (OP, n=15) than in healthy 
subjects (n=10) or patients with renal osteodystrophy (ROD, n=11), as assessed by bone 
histomorphometry and microcomputed tomography (micro-CT). Outliers are depicted as a circle 
and an extreme outlier as a star.  
5.1.2 Reproducibility  
There were no differences between the two repeated measurements with either of the 
techniques (Wilcoxon signed rank test). The values of repeated bone histomorphometry 
measurements for structural parameters BV/TV, Tb.Th, Tb.N, and Tb.Sp exhibited 
correlation coefficients (ρ) between 0.87 and 0.92 (p<0.01), and the CV varied between 8.3 
and 27.2%. The CV of micro-CT parameters for BV/TV, Tb.Th, Tb.N, and Tb.Sp was 4.4-
23.4%. Moreover, Spearman’s correlation coefficients (ρ) were significant (p=0.66-0.94, 
p<0.01). When the groups were compared, there were no significant differences in the 
reproducibility of bone histomorphometry or micro-CT (Kruskal-Wallis test of CV values) 
between the three study groups.  
5.1.3 Agreement  
When all samples were pooled, the correlation coefficients between the micro-CT and 
histomorphometry measurements were significant for BV/TV (ρ=0.54, p<0.01), BS/BV 
(ρ=0.51, p<0.01), Tb.Th (ρ=0.62, p<0.01), and Tb.N (ρ=0.39, p<0.05). Correlations between 
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BV/TV (micro-CT) and mineralized bone volume (Md.V/TV, histomorphometry) were 
slightly weaker (ρ=0.53, p<0.01) than between BV/TV (micro-CT) and BV/TV 
(histomorphometry) (ρ=0.54, p<0.01). When the groups were analyzed separately, OP 
samples showed significant correlations for BV/TV (ρ=0.58, p<0.05) and for Tb.Th (ρ=0.64, 
p<0.05). 
 
Table 11. Bone histomorphometry and micro-CT parameters in different study groups.  
 
Bone 
histomorphometry ALL   NORMAL  OP   ROD     
 MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD 
BV/TV (%) 19.1 ± 6.4 22.1 ± 5.0 14.8 ± 5.7 22.3 ± 4.8 
OV/BV (%)   3.1 ± 2.4 2.8 ± 2.8 2.2 ± 1.4 4.7 ± 2.2 
OS/BS (%)  23.3 ± 14.6 23.2 ± 16.9 16.3 ± 9.9 32.9 ± 12.5 
ES/BS (%)  4.7 ± 4.4 3.2 ± 3.0 3.1 ± 2.3 8.2 ± 5.6 
Ob.S/BS (%)  2.3 ± 3.0 0.4 ± 0.8 1.8 ± 2.8 5.0 ± 2.6 
Oc.S/BS (%)  2.5 ± 3.3 1.6 ± 2.6 1.2 ± 1.4 5.2 ± 4.3 
O.Th  (μm)  6.5 ± 1.8 7.1 ± 2.1 5.7 ± 1.3 7.1 ± 1.6 
Tb.Th (μm)  104 ± 28 121 ± 25 94 ± 31 103 ± 21 
Tb.N (1/mm)  1.9 ± 0.5 1.9 ± 0.5 1.6 ± 0.5 2.2 ± 0.4 
Tb.Sp (μm)  489 ± 238 446 ± 141 605 ± 306 370 ± 95 
MS/BS (%)  5.4 ± 5.1 1.8 ± 2.1 4.7 ± 5.2 7.2 ± 4.9 
MAR (μm/day)  0.36 ± 0.28 0.25 ± 0.29 0.38 ± 0.30 0.35 ± 0.25 
W.Th  (μm)  36.6 ± 7.3 34.9 ± 5.4 37.0 ± 8.8 36.4 ± 5.2 
MicroCT-3D                         
BV/TV (%) 18.2 ± 5.6 20.8 ± 4.7 14.7 ± 5.5 20.7 ± 3.9 
BS/TV (1/mm)  4.3 ± 1.1 4.6 ± 1.1 3.8 ± 1.2 4.9 ± 0.8 
SMI 1.3 ± 0.5 1.3 ± 0.5 1.6 ± 0.5 1.0 ± 0.3 
Tb.Th (μm)  150 ± 25 164 ± 17 143 ± 27 145 ± 22 
Tb.N (1/mm)  1.2 ± 0.4 1.3 ± 0.3 1.0 ± 0.3 1.4 ± 0.3 
Tb.Sp (μm)  603 ± 160 602 ± 230 631 ± 141 567 ± 96 
 
 
5.2 ATYPICAL FEMORAL FRACTURES (II) 
5.2.1 Incidence  
We identified eight patients with AFFs among the trauma patients in our hospital from 
January 2007 to December 2009. Two of these patients had bilateral fractures (not 
simultaneously), i.e., a total of 10 fractures. Six of these patients had been treated with BPs 
for several years prior to the AFF. Alendronate had been in use in five patients whereas 
only one patient, who had been on multiple BP treatments, was been treated recently with 
ibandronate. The mean age of the patients at the time of fracture was 71.2 years (range 55.5-
89.9 years). The mean treatment duration with BPs before the fracture was 7 years (range 4-
10 years). Only limited data for bone density was available. Patient #1 had BMD T-score -0.7 
in lumbar spine, -1.2 in left femoral neck, and -0.4 in the upper part of the femoral diaphysis 
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on the left. Patient #7 had lumbar spine BMD T-score -2.8 and right femoral neck BMD T-
score -0.4. 
In the years 2007-2009, the mean population who were aged 50 years and over in the 
catchment area of Kuopio University Hospital was 103 932 inhabitants, of which 55 539 
were women. During these years, the average number of patients on continuous BP therapy 
in the area was 4379. We calculated the annual occurrence of AFFs to be 3 per year. Two 
patients (with unilateral fractures) had not been receiving BP treatment. The incidence of 
fractures in BP-treated patients was 2.67 fractures per year and there were 4379 patients on 
BPs in the catchment area of our hospital. The incidence was therefore 2.67/4379 per year = 
0.61/1000 per year for BP users (95% CI: 0.13/1000 - 0.92/1000), compared to 0.0067/1000 
(95% CI: -0.0026/1000 - 0.016/1000) per year for untreated patients.  
5.2.2 Histological bone findings  
The patients (n=4), that underwent bone histomorphometry, were postmenopausal women 
(aged 55.5 – 81.1 years). None of the patients experienced any complications during or after 
the bone biopsy procedure. Cancellous bone volume (BV/TV) and trabecular thickness were 
low in 3 patients, osteoid surface (OS/BS) and osteoblasts surface (Ob.S/BS) were low in 2 
and mineralizing surface (MS/BS) was low in all 4 cases (Figure 10).  Further, erosion 
surface (ES/BS) was low in 3 cases. These findings suggest for low bone formation in 3 out 
of 4 patients.  For patients #1 and #4, the tetracycline labeled biopsies were taken five and 
two months after the first unlabelled biopsy, respectively. By fluorescence microscopy, 
single labels were detected in the cancellous region of interest in only Patient #3 (MS/BS, 
0.8%) who also had an increased amount of osteoid (OV/BV, 7.1%) and a higher fraction of 
osteoblasts of bone surface (Ob.S/BS 10.9%).  
Since there were no labels in regular cancellous ROI, extended label search was 
performed. Patient #1 had one short single label in cortical bone but no cancellous bone 
labeling. Patient #2 had one double label in cortex together with one double label in a 
cancellous bone in one section. Another section had a cortical single label. Patient #3 had 
one double label in cancellous bone and a single label in cortex in one section. A cortical 
single label in two sections was found for Patient #4, and the other section of these included 
two short single labels in cancellous bone.  
5.2.3 Bone composition findings  
The bone composition measured by FTIRI showed higher degree of mineralization 
(phosphate-to-amide I ratio) in 3 of our 4 patients. Carbonate-to-phosphate ratio was within 
the normal range. Higher carbonate-to-amide I and collagen cross-link ratios were found in 
3 of our 4 patients with AFFs compared with normals. Hence, the collagen cross-link 
maturity might be higher in patients with AFFs. The heterogeneity for phosphate-to-amide 
I ratio was lower for patients with AFFs when compared with normal samples, whereas the 
heterogeneity of carbonate-to-phosphate ratio and carbonate-to-amide I ratio were within 
the normal range.  
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Figure 10. Bone histomorphometry findings in patients with atypical femoral fractures. Bone 
volume tended to be low (green areas, Masson Goldner stain) (a). Bone formation was low in 3 
of our 4 patients (b). Under fluorescence microscopy, most patients showed no fluorochrome 
labeling (c). Double tetracycline labels were found in cancellous bone in two patients including 
the extended label search and single labels in the other two patients suggesting that 
mineralization of bone was obviously decreased but not absent (d). Magnification a) 20×, b-d) 
200×.  
 
 
5.3 VERTEBRAL FRACTURES AND BONE DISEASE AFTER SOLID ORGAN 
TRANSPLANTATION IN CHILDREN  
5.3.1 Clinical characteristics (III, IV)  
Bone characteristics were studied in two cohorts of children who were suspected for 
osteoporosis. The cohort of fracture-prone children included 24 children (17 males) who 
were suspected for primary osteoporosis (Study III). The median age was 12.0 years (range 
6.7-16.6 years) (Table 12). Mäyränpää et al. (2011) has previously studied the correlation 
between bone biopsy findings and clinical, radiological, and biochemical parameters. The 
effect of age on compositional bone parameters was studied by dividing all samples into 
three sub-groups according to age. Increased carbonate substitution into hydroxyapatite 
crystals with age was indicated by the lower carbonate-to-phosphate ratio in the younger 
children (6.7-10.9 yrs, n=9) than in the older children (14.0-17.0 yrs, n=5). Carbonate-to-
phosphate heterogeneity correlated positively with Tanner stage (ρ=0.46, p=0.023) (Figure 
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11a). Bone histomorphometry parameters were correlated with bone compositional 
heterogeneity variables. Collagen cross-link heterogeneity correlated positively with 
OV/BV absolute value (ρ=0.43, p=0.035) (Figure 11b) and O.Th Z-score (ρ=0.45, p=0.029). The 
heterogeneity of carbonate-to-phosphate ratio correlated positively with O.Th absolute 
value (ρ=0.48, p=0.019) (Figure 11c).  
 
 
Figure 11. Significant correlations between bone composition parameters and other variables 
were found. The heterogeneity of carbonate-to-phosphate ratio correlated positively with 
Tanner stage, and thus, children prior to or in puberty might have a more uniform carbonate-
to-phosphate content than children in more advanced puberty (ρ=0.46, p=0.023) (a). Further, 
the heterogeneity of collagen cross-links correlated positively with osteoid surface (OV/BV, 
ρ=0.43, p=0.035) suggesting narrower collagen cross-link ratio in children with lower amounts 
of osteoid (b). The heterogeneity of the carbonate-to-phosphate ratio correlated positively with 
osteoid thickness (O.Th, ρ=0.48, p=0.019) (c). Therefore, the children with low O.Th might 
have a more uniform carbonate-to-phosphate content.   
 
The other cohort (Study IV) included 19 children (age range 7.6-18.8 years, 11 males) 
with a history of solid organ transplantation at 4.6 years (median, range 0.6-16.3 years) 
earlier (Table 12). The median height Z-score was -0.8 and the Z-score was below -2.0 in 
three children (16%); liver transplant recipients had milder growth deficit than kidney 
transplant recipients (p<0.05). BMI ranged from 14.0 kg/m2 to 36.1 kg/m2. The median BMI 
Z-score was -0.1 (range -2.2 to +3.3). Three children were overweight (BMI > +1.0 SD) and 
three children were obese (BMI > +2.0 SD). All patients were on triple-drug 
immunosuppressive medication including cyclosporine A (n=15), tacrolimus (n=4), 
azathioprine (n=11), or mycophenolate mofetil (n=8), and on low-dose alternate-day 
methylprednisolone (n=19). All children were receiving vitamin D substitution. One child 
had prolonged pain at the bone biopsy site for two weeks. None of the patients experienced 
any other complications during or after the bone biopsy procedure.  
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Table 12. Clinical characteristics of children with suspected osteoporosis. The median (range) or 
number of patients are presented.  
 
 Fracture-prone children   (n=24) 
Children after solid organ 
transplantation (n=19) 
Age (years) 12.0 (6.7-16.6) 15.5 (7.6 to 18.8) 
Males / Females (n) 17 / 7 11 / 8 
Height Z-score 0.4 (-1.4 to 2.1) -0.8 (-2.4 to 0.9) 
BMI Z-score 0.7 (-2.3 to 2.3) -0.1 (-2.2 to 3.3) 
Lumbar BMD Z-score  -1.2 (-3.1 to 1.0) -2.0 (-3.9 to 0.4) 
BV/TV < -1.0 SD in histomorphometry (n) 7 6 
Children with non-vertebral fracture(s) (n) 22 4 
Children with vertebral compression(s) (n) 14 11 
5.3.2 Bone densitometry and fractures (III, IV)  
The lumbar BMD Z-score tended to be low in both cohorts. Five fracture-prone children 
(21%), and similarly, nine transplant children (47%), including 7 liver and 2 heart transplant 
patients, had low lumbar spine BMD Z-score (<-2.0 SD) in DXA. A low total hip BMD Z-
score was observed in five transplant children (26%), i.e, one kidney and four liver 
transplant recipients (Study IV). All but two fracture-prone children (92%) had sustained 
peripheral fractures and 14 children (58%) had suffered vertebral compressions. One fifth 
(21%) of the transplant children, all liver transplant recipients, had sustained peripheral 
fractures whereas vertebral compressions were found in more than half (58%) of the 
children. Vertebral compressions were found in all transplant groups.  
5.3.3 Biochemistry (III, IV)  
In fracture-prone children, the plasma PTH concentration (P-PTH, reference range 8-73 
ng/L) correlated with the carbonate-to-phosphate ratio (Spearman’s correlation coefficient, 
ρ=0.41, p<0.05) (Study III) (Figure 12). The other biochemical markers showed no correlation 
with the compositional bone parameters.  
 
Figure 12. In fracture-prone children, plasma parathyroid hormone (PTH) level correlated 
positively with carbonate-to-phosphate ratio as assessed by Fourier transform infrared 
spectroscopic imaging (ρ=0.41, p<0.05). This pointed to an increased carbonate substitution 
into hydroxyapatite crystals among children with higher PTH level.  
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In the cohort of transplantation children, one child had mild hypovitaminosis D (S-25-
OHD 43 nmol/L) whereas the other children were vitamin D sufficient (Study IV). The P-
PTH level was slightly elevated in two children (74 ng/L and 77 ng/L). Ionized calcium 
levels were normal in all children. A low phosphate level was found in two kidney 
transplant children but hyperphosphatemia was not detected in any of the children. Mildly 
elevated P-ALP was found in two children. Creatinine was elevated (95-134 μm/L) in eight 
children from different transplant groups. Only one child had normal kidney function 
whereas all other of the children had mild (CKD stage 2, n=9) or moderate (CKD stage 3, 
n=9) kidney failure. The kidney transplant recipients had more severe kidney dysfunction 
than the liver transplant recipients (p<0.05).  
5.3.4 Cancellous bone volume in biopsy (III, IV)  
A low cancellous bone volume (BV/TV < -1.0 SD) was observed in 7 fracture-prone children 
(29%) and in 6 children (32%) after transplantation. There was no significant difference in 
cancellous bone volume between the transplant groups (Figure 13). In both cohorts, the 
children with low cancellous bone volume in biopsy (BV/TV < -1.0 SD) were compared to 
those with a normal bone volume (BV/TV ≥ -1.0 SD). In fracture-prone children, the 
carbonate-to-amide I and carbonate-to-phosphate ratios were lower for children with low 
BV/TV (n=7, p<0.05) when compared to children with normal bone volume (n=17) (Study 
III). This suggests that there is a lower level of carbonate substitution in crystals in children 
with low cancellous bone volume. In the transplantation cohort, children with low BV/TV 
(n=6) had thinner trabeculae (Tb.Th median -3.1 SD, range -5.0 to -2.2 SD) and higher 
trabecular separation (Tb.Sp median -0.5 SD, range -2.6 to +3.5 SD) than those with normal 
BV/TV (n=13, Tb.Th median -2.1 SD, range -3.7 to -0.7 SD; Tb.Sp median -2.2 SD, range -3.9 
to -1.2 SD; p<0.05, Study IV). A trend was seen for lower trabecular number (Tb.N median 
1.4 SD, range -1.9 to +6.3 SD, p=0.054) and higher mineral apposition rate higher (MAR 
median -0.7 SD, range -2.4 to +1.4 SD, p=0.053) in children with low BV/TV as compared to 
children with normal BV/TV but this was not statistically significant. 
 
 
Figure 13. No significant differences between the different transplant groups (kidney, liver, and 
heart) were found for cancellous bone volume (BV/TV Z-score, p>0.05). Tx=transplantation.  
5.3.5 Fracture-prone children with and without vertebral fractures (III)  
Fracture-prone children with a previous a vertebral fracture (n=14) showed different bone 
composition compared with those without vertebral fractures (n=10). There was no 
significant difference in age between the study groups. There was no significant difference 
in the phosphate-to-amide I ratio, whereas the carbonate-to-phosphate ratio and the 
heterogeneity of carbonate-to-phosphate ratio were lower (p<0.05) in children with 
vertebral fracture. This is evidence of decreased and narrower carbonate substitution in 
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subjects with vertebral fracture compared to children without vertebral fracture. The 
collagen cross-link ratio (p<0.05) was higher and the heterogeneity of collagen cross-link 
ratio was lower (Figure 14) in children with vertebral fractures. Hence, the number of 
mature collagen cross-links might be higher and more uniform in children with vertebral 
fracture. There was no significant difference in crystallinity between the children with and 
without vertebral fracture. 
 
 
Figure 14. Based on FTIRI, the heterogeneity of carbonate-to-phosphate ratio and the 
heterogeneity of collagen cross-link ratio were lower in fracture-prone children with vertebral 
fracture compared to those without vertebral fracture (p<0.05, *). This points to more uniform 
collagen composition of bone in children with vertebral fracture than in children without 
vertebral fracture.  
 
The histomorphometric evaluation revealed a low cancellous bone volume in 36% of the 
children with a vertebral fracture. The bone turnover rate was abnormal in 64% of the 
children who had sustained vertebral fracture. According to the biochemistry evaluation, 
children with and without vertebral fractures had no significant differences in biochemical 
data including levels of 25-hydroxyvitamin, PTH, ALP, P1NP, and 1CTP. 
 
5.3.6 Histological findings in children after solid organ transplantation (IV)  
Thin trabeculae and increased trabecular number were observed in 14 children (74%), i.e., 
increased trabecular separation was found in only one child (Table 13). Abnormal turnover 
findings were common in pediatric transplant patients: seven of the children (37%) had a 
high turnover whereas six children (32%) had a low turnover. Increased osteoid thickness 
(> +2.0 SD) was found in four children (21%) of whom one had received kidney and three 
liver transplants. Children with thick osteoid seams (O.Th > +3.0 SD, n=3) had normal 
labeling, i.e., no mineralizing defect nor any signs of osteomalacia were found. Two of the 
18 children with appropriate tetracycline administration had no labels in the region of 
interest. In the extended label search the other patient had one subcortical double label and 
the histological classification remained as low bone turnover. The other patient had no 
labeling in the extended label search and the histological diagnosis was adynamic bone 
disease. In addition, in one child’s labels were lacking because no tetracycline had been 
given prior the biopsy.  
After excluding the children without labeling (n=3, extended label search), the dynamic 
bone histomorphometry parameters (MS/BS; MAR; BFR/BS, and Ac.F) tended to be low-
normal; there were no significant differences between the different transplant groups. The 
different turnover rates were compared. Six children (32%) had normal turnover rate in the 
biopsy. These patients had a low lumbar BMD Z-score (median -2.3 SD, range -2.0 to -1.0 
SD), and two of these children had low BV/TV (< -1.0 SD) by histomorphometry. Four of the 
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six children with normal turnover had vertebral compressions but none had sustained 
peripheral fractures. 
Children with higher present GC dose (≥ 3mg/d) had lower Oc.S/BS and osteoid 
maturation time (Omt) than children with the lower GC dose (1-2 mg/d, p<0.05). No 
significant differences in absolute histomorphometry values were found between children 
with GC exposure exceeding 1000 days as compared to those with a shorter GC exposure. 
A negative correlation was found between the GC dose at the time of biopsy and Oc.S/BS 
Z-score (ρ=-0.55, p=0.016). The Oc.S/BS Z-score correlated positively with the time from 
transplantation to the biopsy (ρ=0.66, p=0.002) and lumbar BMD Z-score (ρ=0.47, p=0.043). 
CG exposure correlated negatively with lumbar BMD Z-score (ρ=-0.46, p=0.046). 
No significant differences in any of the bone histomorphometry values (Z-scores) were 
detected between the subjects with normal and mild or moderate kidney insufficiency. 
Children with normal or mild kidney dysfunction were younger and more recently 
transplanted, had lower lumbar BMD Z-score, S-25-OHD, and P-Ca level, but possessed 
similar serum phosphate levels, as children with moderate kidney dysfunction (p<0.05). 
Children with compression fracture (n=11) had lower MS/BS, BFR/BS, and Ac.F than 
children without (n=8) vertebral compressions (p<0.05). The subjects with compression 
fractures also had higher present (median 2mg, range 2-5mg, p=0.022) and cumulative GC 
dose (4172mg, range 2188-10 133mg, p=0.023), and lower P-ALP (94 U/L, range 74-321 U/L, 
p=0.026) than those without compression fractures (present GC dose median 1.5 mg, range 
1-4 mg; cumulative GC dose median 2080 mg, range 1095-3939 mg; and P-ALP 172 U/L, 
range 96-301 U/L). 
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6  Discussion 
In this study, the qualitative properties of bone were investigated using different techniques. 
Bone remodeling and mineralization were characterized using quantitative bone 
histomorphometry in certain cohorts of adult and pediatric patients. In specific cohorts, studies 
of the bone microarchitecture or composition were performed using micro-computed 
tomography or Fourier transform infrared imaging. Bone compositional changes in pediatric 
patients with vertebral fractures have not been reported previously, and thus, this study 
provides an insight into these changes. Bone histomorphometric findings in pediatric patients 
after solid organ transplantation have been described only in one previous report (Sanchez et al. 
1998). That study reported findings in children after renal transplantation, whereas in this 
thesis, findings in pediatric patients after liver and heart transplantation are also presented. 
6.1 DATA COLLECTION AND VALIDATION 
In an attempt to decrease the relatively high inter-observer variations (de Vernejoul et al. 1981; 
Chavassieux et al. 1985; Compston et al. 1986; Wright et al. 1992), the samples were measured 
by the same observer in bone histomorphometry. Study II is one exception to this rule, since the 
mean value from two observers was used in the analysis.  
This study combined different techniques to study bone quality and the invasive techniques 
were correlated with clinical characteristics. Furthermore, the PMMA embedded bone biopsies 
were suitable for all invasive techniques in this study. Based on the previous literature in FTIRI, 
the PMMA spectrum was subtracted from every bone spectrum to account for the differences in 
PMMA penetration into the trabeculae (Boskey and Mendelsohn 2005). In micro-CT, it is 
believed that embedding to PMMA had only insignificant effects on the micro-CT 
measurements. In fact, a previous study showed that the structural micro-CT parameters of the 
cancellous bone sample were not significantly affected by the surrounding medium (Perilli et al. 
2007).  
Bone histomorphometry has advanced our understanding of the cellular changes in bone 
diseases. For example, the rapid early bone loss related to GC-treatment and organ 
transplantation was detected by histological analysis instead of via biochemical markers of bone 
turnover (Vedi et al. 1999; Dalle Carbonare et al. 2005).  Information about bone turnover and 
BMD may be acquired using serum bone turnover markers and densitometry. However, these 
methods cannot differentiate lamellar or woven bone structure, or detect a mineralizing defect 
or adynamic bone disease. Further, one cannot gather information about mechanisms involved 
in bone loss or gain (Compston 2004). In contrast, bone histomorphometry provides insight into 
these aspects.  
Histomorphometry is a two-dimensional, invasive technique. It is time consuming and the 
technique requires high expertise and training (Compston 2004; Dempster et al. 2013). 
Nonetheless, many of the currently available techniques to measure bone quality, such as 
micro-CT or FTIRI, require an invasive bone biopsy. When studying bone microarchitecture, the 
three-dimensional approaches provide better resolution than two-dimensional bone 
histomorphometry (Compston 2004; Recker et al. 2011). When comparing the correlation of two 
repeated histomorphometry measurements on bone cell-counts, the correlation was lower 
among osteoporotic than among renal osteodystrophy samples. This may be explained by the 
lower number of bone cells in osteoporotic bone, and the consequently higher relative error of 
small miscalculations. The selection of the ROI is more critical in histomorphometry, since the 
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measured tissue area is smaller than the measured tissue volume in three-dimensional 
techniques. As regards to other limitations of bone histomorphometry, there may be 
considerable heterogeneity in bone remodeling and turnover between the different anatomical 
sites not only in diseased subjects but also in healthy individuals. In all of the studies, only iliac 
crest biopsies were investigated and the reference values for each sub-study were obtained from 
the same anatomic location (Recker et al. 1988; Glorieux et al. 2000). Histomorphometry cannot 
be repeated frequently for obvious ethical reasons but also because bone remodeling accelerates 
after the bone biopsy procedure. Thus, only one biopsy from each iliac crest can be used in one 
patient (Compston 2004). 
The studies in this thesis are limited by their relatively low number of samples. In particular, 
the small size of the subgroups may have prevented from identifying other differences. Bone 
histomorphometry is a time-consuming technique and needs an invasive bone biopsy. Thus, the 
number of samples has been small also in previous studies (Compston et al. 1986; Jordan et al. 
2003; Mäyränpää et al. 2011). Further, there was variation in the sample size due to sample 
collection and preparation problems. In each study, one to two sections were randomly selected 
for the histological analysis. Therefore, the results are based on a relatively small tissue area 
compared to three-dimensional techniques such as micro-CT. In Study I, micro-CT 
measurements were conducted after histomorphometry. Therefore, the exact same bone area 
could not be measured with both techniques. Additionally, mechanical testing of the samples 
would have improved the understanding of fracture resistance in these cohorts.  
The limited data of biochemistry and bone densitometry in Study II was a shortcoming. Due 
to the retrospective nature of the data collection, it was not possible to collect further 
information at the time of the fracture. The BMD prior to the BP treatment was not available. 
Further, a relatively long time had elapsed since the fracture in one case of the patients with 
AFFs. Although one patient had fallen from a stack of wood that was 0.5 meters high, this was 
regarded as a low energy trauma, and she was included into the study because the other 
characteristics of AFF were present.   
Ideally the histomorphometric findings should be compared with age- and gender-matched 
healthy control subjects whose biopsies are prepared and analyzed similarly to the patients' 
biopsies. In this study, this kind of control data was unavailable. The Finnish reference data 
includes only static histomorphometric values in adults, and therefore, was not suitable for this 
study (Hoikka and Arnala 1981). There is only a limited number of publications about 
histomorphometric normal values. In this study, the results were compared with the literature 
controls, using the normative data that have been published for both pediatric and adult 
patients (Recker et al. 1988; Glorieux et al. 2000). In Study II, a control group of patients with 
typical femoral fractures would have been of value. Access to a healthy control group for 
compositional bone variables would have improved Study III but unfortunately no such 
normative data in children is currently available. A positive control group might have 
improved the outcome.  
The histological classifications used in this study differ somewhat from the previous studies 
because of the great variety of classifications (based on cut-off values and reference data) used 
earlier both in children and adults (Salusky et al. 1988; Hutchison et al. 1994; Alon 2001). We 
used age-specific reference data and standard deviations as cut-off limits which made it 
possible to have a classification subdivided by age groups. According to the recent 
recommendations for the classification of CKD in adults, specified criteria have been presented 
(Moe et al. 2006). However, osteoporosis, osteomalacia, CKD-MBD, and adynamic bone disease 
still remain poorly understood and inadequately defined in children. There is a need for 
accurate definitions for the histomorphometric diagnosis in pediatric patients. 
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6.2 ASSESSMENT OF BONE QUALITY 
6.2.1 Bone histomorphometry 
This study assessed histological findings in patients with AFFs and in children with suspected 
secondary osteoporosis after solid organ transplantation. The bone histomorphometry findings 
were heterogeneous and the clinical characteristics, e.g. biochemistry or densitometry, poorly 
predicted the histological findings.  
It has previously been shown that fracture-prone children displayed heterogeneous findings 
by bone histomorphometry. The histomorphometric findings showed poor correlation with 
fracture history, serum bone turnover markers, and densitometry (Mäyränpää et al. 2011). In 
children with suspected secondary osteoporosis after organ transplantation, bone 
histomorphometry showed that abnormal bone biopsy findings in various parameters reflecting 
bone quantity, quality, or dynamics were common. All these children had been on GC 
treatment and were suspected to have secondary osteoporosis according to their fracture 
history and/or low BMD. The biochemical markers poorly predicted histological findings. 
Only limited data of bone histomorphometry in patients with AFF is available. Among a few 
patients with AFFs, there have been reports of severely suppressed bone turnover rate both in 
the iliac crest and in the fracture site (Odvina et al. 2005; Shane et al. 2010). Bone 
histomorphometry revealed low cancellous bone volume in three of the four patients. Scarce 
tetracycline labeling was present as described previously (Odvina et al. 2005; Shane et al. 2010). 
However, similar findings have been observed even in untreated postmenopausal women 
(Whyte et al. 1982; Hauge et al. 1999). Due to existing labeling in the biopsy in ROI or outside it, 
mineralization although low does not seem to be totally absent. However, if only mineralization 
was low and bone formation was normal, thicker osteoid seams would follow, and this was not 
the case in our patients. This suggests that both low turnover and low mineralization may 
coexist in some of our cases. The low labeling by tetracycline without osteoid accumulation 
could be explained by the low bone formation rather than exclusively by bone mineralization 
defect.   
 
Tetracycline labeling and related problems 
The nomenclature, symbols, and units used in bone histomorphometry follow the standardized 
recommendations by ASBMR (Parfitt et al. 1987; Dempster et al. 2013). The anti-resorptive 
agents, such as BPs, have created new challenges for bone histomorphometry. The mechanism 
of these drugs may suppress bone resorption significantly leading to only a few or absent 
fluorochrome labels in the ROI. This may create difficulties in the interpretation in the dynamic 
indices and bone remodeling status (Recker et al. 2011).  
Based on the recommendations, the variables describing bone remodeling were applied in 
this study. The mineralizing surface (MS/BS) is the best variable to describe the extent of 
remodeling surface in any sample. Based on MS/BS, other dynamic indices can be calculated. 
Mineral apposition rate (MAR) describes the rate at which the mineral accretion occurs during 
bone formation at the remodeling site. It is one of the fundamental parameters that reliably 
measure osteoblast function. In the case of scarce double labeling or even the absence of the 
double labels in the biopsy, MAR cannot be calculated, as was the case in some of the patients 
in this study. For reliable calculation of MAR, a minimum of two independent double labels 
including at least five measurements should be performed (Recker et al. 2011). In a human 
cohort, the lowest MAR reported has been 0.3 μm/day (Foldes et al. 1990). If MAR cannot be 
measured, this so-called ‘imputed MAR’ value could be used. Otherwise, the zero value of 
MAR should be reported as ‘missing data‘. Bone formation rate (BFR/BS) is a more complex 
variable describing the bone remodeling status. Activation frequency (Ac.F) is a further derived 
parameter that describes the probability (#/year) of the initiation of a new remodeling cycle at 
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any point on the trabecular surface. It represents the number of currently active BMUs. Ac.F is 
the best two-dimensional index currently available to measure the intensity of bone remodeling 
or turnover (Recker et al. 2011). 
In cases of absent or insufficient double labels in ROI, a limited extended label search could 
be performed. The examined sections should be studied to identify labeling outside the ROI 
including cortical bone to assure that the patient has actually taken the fluorochrome labeling. 
A telephone contact to follow tetracycline labeling in research purposes is recommended. If 
labeling outside the ROI in the two examined sections (300 μm apart) is found, no further 
investigations are necessary. The absence of double labels in the standard ROI certainly 
indicates low bone remodeling (Recker et al. 2011). In this study, extended label search was 
carried out because of the possibility for oversuppression caused by BPs in patients with AFFs 
and to assure the extension of tetracycline labeling in the three children with absent labeling. In 
fact, one of these children had not taken the tetracycline tablets, and histological classification 
was made based on low static formation parameters. One patient had no trabecular labels but 
due to the subcortical double label and relatively high OV/BV, which were suggestive of the 
presence of osteoblast activity, this could not be classified as adynamic bone disease and the 
thin osteoid seams excluded the possibility of osteomalacia. The only patient with adynamic 
bone disease had no labels at all, low cancellous bone volume, generally low bone formation as 
well as low bone resorption. 
 
Bone histomorphometry findings in children  
There are no established cut-off values (e.g. SD-values) for the various histomorphometric 
parameters to define osteoporosis in children. In these studies, low cancellous bone volume was 
defined as a BV/TV Z-score below -1.0 compared to the age-matched reference values (Glorieux 
et al. 2000). Similar cut-off limits have been used before (Mäyränpää et al. 2011). In the 
histomorphometric evaluation, low cancellous bone volume was measured in 36% of the 
fracture-prone children with a vertebral fracture. However, low cancellous bone volume was 
also found in 20% of cases without vertebral fracture, and all these children had sustained 
peripheral fractures. In children with organ transplant, low cancellous bone volume was 
observed by histomorphometry in only one third (32%) of the patients whereas low lumbar 
BMD Z-score (below -2.0) was found in half (47%) of the children. Despite the normal 
cancellous bone volume, the trabecular architecture was often altered and was characterized by 
thin trabeculae and increased trabecular number. Since most of the patients had normal height 
and skeletal maturation, these changes are likely to reflect true alterations of bone quality 
having an adverse effect to bone strength and fracture resistance. 
The bone turnover rate was abnormal in 64% of the fracture-prone children. Mäyränpää et al. 
has previously shown that vitamin D deficiency was associated with a high turnover in the 
biopsy in these children (Mäyränpää et al. 2011). Abnormal bone turnover findings were also 
frequent in children after a solid organ transplantation since only one third (32%) of the 
children had normal bone remodeling. A high turnover was present in 37% and low turnover in 
32%, including one with an adynamic bone disease. The findings were heterogeneous, and the 
transplanted organ did not predict the histological findings. The prevalence of adynamic bone 
disease or mineralizing defect in children is highly dependent on the reference values being 
used, and the definitions vary greatly both in adult and pediatric patients (Salusky et al. 1988; 
Hutchison et al. 1994; Alon 2001; Edouard et al. 2011). The histological classification used in 
Study III (low, normal, or high turnover) was further improved in Study IV to also detect a 
mineralizing defect and adynamic bone disease. An abnormal turnover rate in combination 
with altered bone architecture rather than actual loss of cancellous bone volume might explain 
the increased fracture risk in children after solid organ transplant; true adynamic bone disease 
seems to be rare. In conclusion, there are no specific rules for classifying the turnover rates in 
children. There is a need for accurate definitions for the histomorphometric diagnosis in 
pediatric patients. 
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Complications after bone biopsy 
The complication rate after the bone biopsy procedure in the current study was low. This 
concurs with previous studies (Duncan et al. 1981). The 4 patients assessed due to an AFF 
experienced no complications during or after the bone biopsy procedure. In the fracture-prone 
children, one superficial skin infection was reported, which was treated with oral antibiotics. In 
addition, one child suffered transient nerve symptoms during the operation (Mäyränpää 2012). 
In children after solid organ transplantation, one child felt prolonged pain at the biopsy site but 
no other complications were reported. All children received analgesics (usually a combination 
of paracetamol and ibuprofen) for three days post-operatively. 
6.2.2 Micro-computed tomography (micro-CT) 
Micro-CT enables relatively rapid analysis of bone microarchitecture in three-dimensions. 
Although invasive bone biopsy is needed for the analysis, the same PMMA embedded bone 
block used in bone histomorphometry can be used for the analysis. Some studies have shown 
highly significant correlations between bone histomorphometry and micro-CT for structural 
parameters (Uchiyama et al. 1997; Muller et al. 1998; Chappard et al. 2005) whereas in one other 
study only a weaker correlation was detected (Ito et al. 1998).  In the present study, micro-CT 
showed slightly lower absolute values for BV/TV than those found with histomorphometry. 
The correlation between the techniques for these clinical bone samples, although significant, 
was weaker than has been described in the literature. The previous studies were conducted 
mostly on healthy normal and pathological human cancellous bone combined, whereas the 
present study also categorized the bone samples based on the metabolic status.    
Micro-CT may be used to detect structural changes of the mineralized bone matrix. Micro-CT 
showed better intra-observer reproducibility of the structural parameters (Tb.Th and Tb.N) than 
histomorphometry measurements. The reproducibility was not affected by the health status of 
bone. Micro-CT was able to detect differences between the normal and OP, as well as between 
the OP and ROD groups, but it was less effective than bone histomorphometry in 
distinguishing renal osteodystrophy from normal samples. These results indicate that micro-CT 
can detect osteoid as bone tissue, i.e., separate osteoid from bone marrow with the used 
threshold levels but more studies will be needed to clarify its accuracy. The agreement between 
the techniques was highest in OP samples. Higher correlations are to be expected with a wider 
range of the measured variables. Therefore, the agreement between micro-CT and bone 
histomorphometry in OP patients might simply be a reflection of a greater exposure range in 
these patients compared to ROD or normal samples (Bland and Altman 1996). Micro-CT is a 
reproducible and effective tool for determining structural bone changes. Histomorphometry is 
still needed in clinical practice to study the remodeling balance in bone, and in fact, the 
methods are complementary in the assessment of bone quality. 
6.2.3 Fourier transform infrared spectroscopic imaging (FTIRI) 
FTIRI was used to assess the bone composition in children with suspected IOP with fractures 
and in patients with AFFs. In fracture-prone children, there was increased carbonate 
substitution in hydroxyapatite crystals with age. Fracture-prone children with a previous a 
vertebral fracture had a different bone composition than children without vertebral fractures. 
Children with vertebral fractures exhibited lower carbonate substitution, increased collagen 
cross-link ratio, and narrower heterogeneity of collagen cross-link ratio as compared to children 
without vertebral fractures. In the pooled sample set, the correlations between the biochemical 
and compositional bone parameters were mostly weak, showing only higher carbonate 
substitution in children with higher PTH levels. In patients with AFF, a higher degree of 
mineralization, increased collagen maturity, and decreased heterogeneity of the degree of 
mineralization were observed.  
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In this study, the mineral-to-matrix ratio did not change significantly with age although the 
age-dependent increases in the mineral content and in the mineral-to-matrix ratio have been 
described (Boskey and Pleshko Camacho 2007). The fracture history in all children included in 
this study might explain the findings. The younger children had lower carbonate-to-phosphate 
ratio than the older children, suggesting increased carbonate substitution in hydroxyapatite 
crystals with age. These findings are consistent with those reported in the literature (Paschalis et 
al. 1997; Gadeleta et al. 2000; Huang et al. 2003; Boskey et al. 2005; Faibish et al. 2006). 
In the children with low cancellous bone volume in biopsy (BV/TV <-1.0 SD) the level of 
carbonate substitution in crystals was lower than in children with normal bone volume. 
Additionally, children with vertebral fracture had a lower level of carbonate substitution 
compared to children without vertebral fracture. Carbonate substitution in patients with AFFs 
was normal. The effect of the carbonate substitution on the biochemical and mechanical 
properties of bone is still poorly understood (Ruppel et al. 2006). Some studies have suggested 
that carbonate is an impurity, and therefore decreased substitution would be related to mature 
crystals. Others have suggested that carbonate substitution occurs randomly over time, and 
thus any increases in carbonate substitution would be related to increasing tissue age due to 
decreased turnover. Indeed, carbonate substitution has been shown to increase with age in rat 
and human bone (Akkus et al. 2004; Yerramshetty et al. 2006). Lower carbonate substitution 
may be linked to higher turnover rate or remodeling (Isaksson et al. 2010).    
Previous studies have also indicated that collagen maturity increases with age (Paschalis et 
al. 1997; Huang et al. 2003; Boskey et al. 2005; Faibish et al. 2006). An increased collagen cross-
link ratio and decreased heterogeneity of collagen cross-links were found in children with 
vertebral fractures, as compared to those without vertebral fractures. Similarly, an increased 
collagen cross-link ratio was found in patients with AFFs. Increased collagen maturity in 
cancellous bone has been shown to associate with an increased risk of fractures (Gourion-
Arsiquaud et al. 2009). Increased collagen cross-link maturity has been found in osteoporotic 
bone (Paschalis et al. 2004) and in alendronate-treated postmenopausal women (Bala et al. 2012) 
whereas another study confirmed no difference in alendronate-treated women compared with 
non-treated controls (Boskey et al. 2009). BP-treated patients with femoral fractures have been 
postulated to exhibit a lower heterogeneity of collagen cross-links (Donnelly et al. 2012). Thus, 
altered collagen maturity or its more uniform distribution in the patients of this study may 
explain the greater propensity for developing fractures.  
Lower heterogeneity of phosphate-to-amide I ratio was found among patients with AFFs and 
this coincides with previous findings among postmenopausal women treated with BPs (Boskey 
et al. 2009). The changes in the distribution of mineralization have been claimed to relate to the 
changes in bone remodeling, and therefore, caused by the antiresorptive therapy (Gourion-
Arsiquaud et al. 2009; Donnelly et al. 2012). More homogenized mineral and collagen content of 
the bone may lead to more brittle bone (Gourion-Arsiquaud et al. 2009). Children with a 
vertebral fracture had also narrower distributions of collagen cross-links and carbonate-to-
phosphate ratios. The more uniform bone composition found in the present study cohorts are in 
line with the previous studies and may explain the higher propensity to develop low energy or 
vertebral fractures. 
6.3 CLINICAL CHARACTERISTICS 
6.3.1 Atypical femoral fractures 
Patients who had sustained AFFs in our healthcare district were studied. Eight patients with ten 
AFFs were identified among the patients older than 49 years treated for femoral fractures at 
Kuopio University Hospital during the time period from January 2007 to December 2009. Six of 
these patients were BP users. The annual incidence of these fractures in patients on BP in our 
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hospital’s catchment area was estimated as 0.61/1000 patients. None of the patients suffered 
from diabetes or rheumatoid arthritis, and none of them were receiving GCs or proton pump 
inhibitors. The present results coincide with previous estimates as regards to the incidence of 
AFFs during the BP therapy. The method of our estimate is similar to Schilcher et al., who 
found the incidence of AFFs to be less than 1/1,000 among BP-treated patients in Sweden 
(Schilcher and Aspenberg 2009). In a secondary analysis of three large randomized trials, Black 
et al. proposed the incidence to be somewhat lower, 2.3/10,000 patient-years (Black et al. 2010). 
The patient material of those treatment-trials may differ from that found in everyday practice. 
Further, the radiographs were not reviewed.  This may affect the estimate of incidence as it has 
been proposed that routine radiologic assessment does not detect AFFs sufficiently (Schilcher et 
al. 2011). In the report by Abrahamsen et al., the overall incidence of subtrochanteric femoral 
fractures was similar among alendronate users as among BP-naïve patients with hip fractures 
(Abrahamsen et al. 2009). It is concluded that the incidence of AFFs as the complication of the 
BP therapy seems to be very rare (Shane et al. 2010, Schilcher et al. 2011, Meier et al. 2012).  
None of the patients in this study had malignancy. One patient was excluded from the study 
because of a malignant disease. One patient had suffered a pelvic fracture and bilateral 
diaphyseal femur fractures several years earlier. However, all metal implants had been 
removed years before she sustained an AFF.  
Although the incidence of AFFs seems to remain low, these fractures have a specific 
morphology and occur especially as a result of low energy trauma. Bone formation was 
relatively low in 3 of the 4 patients, as judged by static bone histomorphometry parameters. 
This can be expected after BP treatment. Low mineralization was found due to the scarce 
labeling in the biopsy although double labels were not totally absent. The changes in bone 
composition, i.e., higher degree of mineralization, increased collagen maturity, and decreased 
heterogeneity of the degree of mineralization, could explain the atypically low fracture 
resistance among these patients. Although similar findings have been reported among non-BP-
treated postmenopausal women, the patients with AFF most likely have some other 
concomitant factors that predispose to these fractures. More studies are needed to confirm these 
constituents, and to advance our understanding of AFFs. 
6.3.2 Pediatric fracture patients 
The diagnosis of osteoporosis in younger patients is often made based on low BMD and the 
presence of at least one fragility fracture (Ward and Glorieux 2003) which would be considered 
as a sign of osteoporosis in adults. Unfortunately, this means that the diagnosis is often made 
too late (Bianchi 2007). In a retrospective study of a fracture registry, the 5-year fracture risk 
increased markedly with a low BMD Z-score (below -2.0 SD) (Jones et al. 2006). Mäyränpää et 
al. has previously shown that a low lumbar BMD value was associated with high turnover in 
the biopsy in fracture-prone children (Mäyränpää et al. 2011). In the current study, normal BMD 
(within ± 2 SD) was found in 79% of 24 fracture-prone children. However, 92% of all fracture-
prone children had sustained repeated fractures. Additionally, the lumbar BMD value was low 
(below -2 SD) for only four children who had sustained vertebral fracture. BMD as a fracture 
predictor in children has been somewhat controversial. Some studies propose that BMD alone 
seems not to be a good fracture predictor (National Institutes of Health Consensus 2001; Bianchi 
2007) whereas others have found associations with increased fragility (Goulding et al. 2001, 
Goulding et al. 2005, Ferrari et al. 2006). Interestingly, no statistical differences in FTIRI 
parameters were observed between the fracture-prone children with low and normal BMD. 
However, this may be due to the small number of samples in each group. In addition, fractures 
were common in pediatric patients after solid organ transplantation; more than half (58%) had 
vertebral compression fractures and 21% had a history of peripheral fractures. A low BMD 
value was more often present among these children since 9 children (47%) had low lumbar 
BMD.  This can be explained by GC use in all participants, i.e., high GC exposure was 
associated with a low lumbar BMD Z-score.  
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To avoid overestimation of BMD, bone age was adjusted in pediatric patients because 
delayed puberty and delayed skeletal maturity are common in children with chronic illnesses. 
Similarly, GC treatment could explain delayed bone age. In fracture-prone children, bone age 
was adjusted in 10 children; in four children it was delayed and in six children it was advanced 
for more than a year (Mäyränpää et al. 2011). Bone age was delayed over a year in six transplant 
children and these results were adjusted.  
In the pediatric cohorts of this study, a vertebral fracture was defined as a loss of 20% or 
more in the vertebral height as used in previous studies (Genant et al. 1993; Mäkitie et al. 2005). 
Minor compressions from 5% to 20% have been measured in 70% of healthy children but no 
vertebral compression over 20% was found (Mäkitie et al. 2005). Spinal osteochondosis, i.e., 
Scheuermann’s disease, is characterized by wedge-shaped vertebrae usually in the thoracic 
region of the spine in adolescents (Lowe et al. 2007; Masharawi et al. 2009). In this study, the 
timing of the injury could not been assessed by plain radiographs. It is not evident, whether the 
compressed vertebrae were caused by accidental crushing, growth disturbance, or normal 
variation. The preceding pain in younger children is not always reliably recorded. However, as 
shown previously, the loss of vertebral height over 20% was not found in healthy children 
(Mäkitie et al. 2005), and therefore, the reported findings in this study are likely to important.  
The high-energy fractures in pediatric cohorts were justified as a falling height of 3 meters or 
more as well as all motor vehicle accidents (Landin 1983). Similar classification has been used in 
previous studies (Mäyränpää et al. 2010; Mäyränpää et al. 2012). In children, it is often quite 
complicated to find out the actual fracture energy. Therefore, low and moderate energy 
fractures were combined in this study.    
The bone turnover markers were measured in pediatric fracture-prone patients. It has been 
shown in elderly women that bone turnover markers were affected by a recent fracture up to 12 
months (Ivaska et al. 2007). Therefore, it remains unknown whether some differences in bone 
turnover markers are caused by recent trauma or whether they reflect true changes in bone 
turnover. In pediatric transplant recipients, the level of physical activity varied; some on them 
were very active but none of the children were so ill that their ability to exercise would have 
been limited because of their chronic illnesses.   
6.3.3 Chronic kidney disease  
Solid organ transplantation may lead to deterioration of kidney function. As one half of the 
children had normal or mild kidney insufficiency and the others had moderate (stage 3 CKD) 
disease, the role of CKD-MBD in skeletal pathology is likely to be less significant in this group 
compared to those with more severe kidney failure. Recent studies have indicated that 
alterations in skeletal mineralization and mineral homeostasis may be present already in the 
very early stages of CKD (Sabbagh et al. 2012; Wesseling-Perry et al. 2012). This study found no 
differences in histomorphometry between those children with mild or moderate kidney 
insufficiency. Although high turnover in the biopsy was quite common (37%), only one of these 
children had a mildly elevated P-PTH level and all had good P-Ca control. The other mildly 
elevated P-PTH level was found in a child with low turnover in the biopsy. Therefore, the 
biochemical markers do not seem to reliably reflect the bone turnover. All patients in this study 
were given vitamin D substitution and all but one had normal vitamin D status (Study IV). 
Hypovitaminosis D does not seem to be a major contributing factor in post-transplantation bone 
fragility. 
6.3.4 Therapeutic agents 
BPs are commonly used in the treatment of osteoporosis in adults. In selected cases, BPs can 
also be used in pediatric patients. BPs should, however, be avoided in osteomalacia and 
adynamic bone disease, both of which are relatively rare and can be ruled out by 
histomorphometry. This implies in this study that antiresorptive medication may be used in 
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selected pediatric patients for osteoporosis when there is a suspicion of primary osteoporosis or 
after transplantation. 
The prevalence of osteoporosis in children after kidney transplantation despite the 
continuous GC treatment has been lower than expected (Valta et al. 2009), and the present 
findings support this result since only one third (32%) of the children had histologically 
confirmed low cancellous bone volume. It is known that GCs are a risk factor for adynamic 
bone disease (Cueto-Manzano et al. 2003; Freundlich et al. 2004). However, only one patient in 
this study was suffering from adynamic bone disease. Children after transplantation with 
vertebral compressions had higher present and cumulative GC doses than those without 
vertebral compressions. Similarly, high GC exposure associated with low lumbar BMD Z-score. 
Although extensive GC exposure did not result in reduced total bone volume or adynamic bone 
disease, GCs seems to have a role in the development of post-transplantation bone fragility. 
6.4 FUTURE CONSIDERATIONS 
In this study, bone histomorphometry and other sophisticated methods were applied to study 
bone quality. In patients with metabolic bone diseases such as osteoporosis, the definite analysis 
of bone remodeling is currently possible by bone histomorphometry. Serum biochemical 
markers and bone densitometry represent non-invasive approaches which can be utilized to 
assess bone health. Especially in clinically challenging scenarios where different treatment 
options are being considered, bone histomorphometry provides valuable information about 
bone metabolism. The other methods, such as micro-CT or FTIRI, are complementary and 
currently used in research. Based on this study, however, further studies in larger cohorts and 
with prospective follow-up will be needed to address the long-term consequences and clinical 
implications of the histological abnormalities in patients with AFFs, in fracture-prone pediatric 
patients, or in children after solid organ transplantation. Further, FTIRI reference values for 
healthy children should be established to enable proper correlations for findings in pediatric 
patients with suspected metabolic bone diseases. Thus, bone histomorphometry remains a 
valuable tool for studying histological bone changes and will remain such until an accurate 
non-invasive technique is developed.   
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7  Conclusions 
Bone properties in various cohorts were measured using different techniques. The methods 
were complementary. Until progress is made in developing novel non-invasive techniques to 
quantify bone quality, the invasive methods including bone histomorphometry will remain 
important in characterizing the cellular changes in osteoporosis and other metabolic bone 
diseases.  
 
The specific conclusions of the study were: 
 
1. In this study, the agreement between bone histomorphometry and micro-CT using 
clinical bone samples was moderate. The reproducibility was not affected by the health 
status of bone. Micro-CT is a reproducible and effective tool for determining structural 
bone changes. However, it was less effective than bone histomorphometry in 
differentiating renal osteodystrophy from normal samples although osteoporotic 
changes in bone could be successfully detected. Similarly, the agreement between the 
techniques was better for OP than for ROD or normal samples. These results suggest that 
micro-CT can detect osteoid as bone tissue, i.e., separating osteoid from bone marrow 
with the threshold levels in use but more studies will be needed to clarify its accuracy. 
Thus, histomorphometry is still needed in clinical practice to study the remodeling 
balance in bone, and the methods are complementary. 
2. The incidence of AFFs seems to be low. These fractures have a specific morphology and 
occur especially as a result of low energy trauma. Bone formation was relatively low in 
three of the four patients, as judged by static bone histomorphometry parameters. A low 
mineral apposition rate was found due to scarce labeling in the biopsy although double 
labels were not totally absent. The changes in bone composition, i.e., higher degree of 
mineralization, increased collagen maturity, and more uniform degree of mineralization, 
could explain the atypically low fracture resistance among these patients. Although 
similar findings have been reported among non-BP-treated postmenopausal women, the 
patients with AFF most likely have some other concomitant factors (e.g. different 
response to antiresorptive treatment) that predispose them to these fractures. More 
studies will be required to confirm these constituents, and to enhance our understanding 
of AFFs. 
3. An attempt was made to determine whether bone composition differs between the 
fracture-prone children with and without vertebral fractures.  The definition of 
osteoporosis among children and adolescents is complex and the changes in bone quality 
should be detected in the early stages to prevent fractures. The observed changes in bone 
composition, i.e., lower carbonate-to-phosphate ratio and increased collagen maturity in 
children with vertebral fractures might contribute to their greater propensity to sustain 
these fractures.  
4. The bone histomorphometric findings in children who had undergone kidney, liver, or 
heart transplantation were characterized. Histologically reduced cancellous bone volume 
was found in one third (32%) of the patients. In addition, several other abnormal findings 
related to bone microarchitecture and turnover were observed in these children despite 
their relatively good kidney function and controlled P-PTH levels. The observed changes 
in bone quality (i.e., abnormal turnover rate and thin trabeculae) rather than the actual 
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loss of cancellous bone, might explain the increased bone fragility in pediatric solid 
organ transplant recipients. There was extensive heterogeneity in the histological 
findings in different transplant groups, and the results were not predictable by non-
invasive methods. The degree of kidney insufficiency did not explain this variability but 
it is possible that some of the skeletal changes were caused by mild to moderate CKD. 
Thus, bone histomorphometry can provide important information in clinical practice 
with which to characterize the skeletal status in children after solid organ 
transplantation. However, further studies in larger cohorts and with prospective follow-
up are needed to define the long-term consequences and clinical significance of these 
histomorphometric abnormalities. 
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Dual-energy X-ray absorptiometry 
(DXA) is commonly used to measure 
bone mineral density (BMD) and 
to diagnose osteoporosis. However, 
BMD accounts for only 60% of bone 
strength, i.e., changes in bone quality 
as well as density may increase the 
fracture risk. This study aimed to 
characterize bone quality in different 
cohorts of patients using bone 
histomorphometry, microcomputed 
tomography (micro-CT), and Fourier 
transform infrared spectroscopic 
imaging (FTIRI).
